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EXECUTIVE SUMMARY 
1. INTRODUCTION 
1.1. Background 
NICE requested a further evidence review to accompany a series of reviews to support the 
development of tobacco harm reduction (THR) guidance. This rapid review investigated the long 
term use of non-tobacco nicotine containing products (NCPs) in individuals who have attempted to 
quit smoking abruptly rather than via THR approaches.  Long term use of nicotine replacement 
therapy (NRT) has previously been identified as a potential issue in treating nicotine addiction in 
smokers (Hughes, 1998; RCP, 2000). 
For the purposes of this review ‘non-tobacco nicotine containing products’ were defined as NRT 
and ‘electronic nicotine delivery systems’ (sometimes known as ‘electronic cigarettes’ or ‘e-
cigarettes’) and topical gels. NRT is available in the following formulations: chewing gum, 
transdermal patches, inhalers, microtabs, mouth/nasal sprays and lozenges.  
Evidence for individuals who used NCPs long term following THR approaches (cut down to quit 
or long term harm reduction) would have been identified in the two previous THR effectiveness 
reviews.  
It was agreed that a full systematic review was not required but that the SURE team would 
examine studies that were identified through searching for the four THR reviews for any data on 
long term NCP use following an attempt of abrupt cessation; as well as employing snowballing 
techniques to identify other relevant studies concerned with the long term use of NCPs that were 
not identified in the production of the THR reviews. 
1.2. Aim of the review 
To identify and summarise evidence relating to the long term use of NCPs at or longer than 12 
months among abrupt quitters. 
1.3. Research questions 
Information was collected on the following: 
1. Length of time of using NCP 
2. Pattern of NCP use i.e. type of NCP, amount, frequency, reason for use 
3. Demographics of long term users e.g. gender, ethnicity, social determinants 
4. Predictors of long term use 
5. Purchase patterns 
2. METHODS 
A rapid review of evidence relating to long term use of nicotine containing products amongst abrupt 
quitters was carried out. A search was conducted of the Reference Manager databases constructed 
from the comprehensive literature searches carried out for the reviews of the effectiveness of tobacco 
harm reduction approaches and the barriers and facilitators to their implementation (which included 
smoking cessation search terms), as well as the database for the review of the safety, risk and 
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pharmacokinetics profiles of tobacco harm reduction technologies. The original search from which the 
Reference Manager databases were constructed included a wide range of databases and web sites to 
identify a wide range of publications, including grey literature. Searches were limited to studies 
published in the English language between 1990 and 2012. Additional snowballing techniques were 
carried out to ensure relevant publications had been identified. All populations, except pregnant 
women, of all ages were included. 
Interventions, longitudinal and cross-sectional studies were included that examined: 
• Long term use, of 12 months or longer, in those attempting to quit smoking abruptly 
• Purchase patterns, e.g. information relating to over the counter and online purchases 
Study selection was carried out by a single reviewer, with exclusions at the full text screening stage 
being verified by a second reviewer.  Quality assessment and data was extraction was carried out by 
one reviewer and checked by a second. 
A narrative summary of the evidence was carried out; this was supported by evidence statements. 
3. RESULTS 
A total of 18 papers comprising 15 studies were included in the review.  See Table 1 (pp. 14-16) for a 
brief summary of the studies.  Full details are provided in the Evidence Tables (Appendix A). 
Overall, the quality of the 15 included studies varied. Whilst the three RCTs (Blondal 1999 ++, LHS ++ 
[Bjornson-Benson 1993; Murray 1996; Nides 1995], Sutherland 1992 ++) were all assessed as being of 
high quality, only four of the remaining studies, two prospective cohort studies (Hajek 2007 +, 
Schneider 2003 +) and two of the eight cross-sectional surveys  (Etter 2009 +, Etter 2011 +), were rated 
as moderate quality.  
Three studies were from the UK (Hajek 2007 +, Shetty 2010 −, Sutherland 1992 ++) and these were in 
specific populations with Shetty 2010 – having a small sample size. Two studies were conducted in 
Europe (Blondal 1999 ++, Schneider 2003 +). Seven studies were conducted in Canada and the USA 
(Foulds 2011 −, Hatsukami 1993 −, Hughes 2004 −, Johnson 1991 & 1992 −, LHS ++ [Bjornson-Benson 
1993; Murray 1996; Nides 1995], Shiffman 2003 −). Three were internet surveys (Etter 2009 +, Etter 
2011 +, Heavner 2010 −) conducted in English with Etter 2011 + also in French. 
Of the 15 studies, 5 were in a community setting (Blondal 1999 ++, Hatsukami 1993 −, Hughes 2004 −, 
LHS ++ [Bjornson-Benson 1993; Murray 1996; Nides 1995], Shiffman 2003 −). Foulds 2011 – at an 
electronic cigarette enthusiast meeting, Etter 2009 +, Etter 2011 +, Heavner 2010 – were internet 
surveys, Hajek 2007 +, Schneider 2003 + and Sutherland 1992 ++ in a smoker’s clinic or smoking 
cessation unit, Johnson 1991 − and Johnson 1992 – within a health maintenance organization and 
Shetty 2010 – was conducted in a medium secure hospital.. 
4. EVIDENCE STATEMENTS 
4.1. Long term NRT use 
Three studies collected data on a range of NRT products (Hajek 2007 +, Shetty 2010 −, Shiffman 
2003 −). Six studies examined nicotine gum (Etter 2009 +, Hatsukami 1993 −, Hughes 2004 −, 
Johnson 1991 −, Johnson 1992 −, LHS ++ [Bjornson-Benson 1993; Murray 1996; Nides 1995]). Two 
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explored the effect of nicotine nasal spray (Schneider 2003 +, Sutherland 1992 ++). One (Blondal 
1999 ++) looked at the effect of nicotine patch with nicotine nasal spray. 
Evidence Statements:  
4.1 There is moderate evidence of long term (12 months) NRT use in a small number of people 
who had quit smoking. The evidence is provided by three RCTs (Blondal 1999 ++, LHS ++ 
[Bjornson-Benson 1993; Murray 1996; Nides 1995], Sutherland 1992 ++), two prospective 
cohort studies (Hajek 2007 +, Schneider 2003 +) and one UBA (Hatsukami 1993 –). This 
extended use is beyond the length of time that is recommended, treatment is usually 
between eight and 12 weeks before the dose is reduced and eventually stopped. From the 
studies that provided 12-month follow-up data, 7% (range 3-11%) of individuals who had 
quit smoking were still using NRT. This evidence is for nasal spray (Blondal 1999 ++, 
Sutherland 1992 ++, Schneider 2003 +), nicotine gum (LHS ++ [Bjornson-Benson 1993; 
Murray 1996; Nides 1995], Hatsukami 1993 –) and a range of NRT products (Hajek 2007 +). 
4.2 There is moderate evidence that most long term (≥ 12 months) use of nicotine gum or spray 
is within recommended dosage limits. The evidence is provided by two RCTs (Blondal 1999 
++, LHS++ [Bjornson-Benson 1993; Murray 1996]), one prospective cohort study (Schneider 
2003 +) and two cross-sectional surveys (Hughes 2004 –, Johnson 1991 –). For this dosage 
evidence participants in Blondal 1999 ++, LHS++ [Bjornson-Benson 1993; Murray 1996] and 
Schneider 2003 + had quit smoking but the smoking status was not reported for participants 
in Hughes 2004 – and Johnson 1991 –. 
4.3  There is moderate evidence from two studies that nicotine dependence at baseline is a 
predictor of long term NRT use at 12 months (LHS ++ [Bjornson-Benson 1993], Hajek 2007 
+). The data was from participants who had all quit smoking. 
This evidence is directly applicable to people in the UK who attempt to quit smoking abruptly. Of 
the studies that reported NRT use at 12 months in former smokers, two studies were conducted in 
the UK (Hajek 2007 +, Sutherland 1992 ++) and three were conducted in community settings 
(Blondal 1999 ++, Hatsukami 1993 –),LHS ++ [Bjornson-Benson 1993; Murray 1996; Nides 1995]. 
 
4.2. Electronic cigarettes 
Three studies explored the use of electronic cigarettes (Etter 2011 +, Foulds 2011 −, Heavner 2010 
−).  
Evidence Statements:  
4.4 There is no evidence of e-cigarette use for periods of 12 months or longer in individuals who 
quit smoking abruptly and insufficient evidence of the pattern of use. 
4.5 There is weak evidence from three cross-sectional surveys, possibly of e-cigarette 
enthusiasts, (Etter 2011 +, Foulds 2011 –, Heavner 2010 –), that e-cigarettes are used for 12 
months or longer though only Heavner 2010 – states that some individuals have completely 
replaced cigarettes with e-cigarettes. There was no evidence related to the dosage used by 
long term e-cigarette users. 
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4.6 No evidence was identified on predictors or purchase patterns of e-cigarette use. 
The evidence is only partially applicable to people in the UK who quit smoking abruptly. This is 
because e-cigarettes are not licensed for smoking cessation. However the evidence does indicate 
that e-cigarettes are used in the UK (Etter 2011 +, Heavner 2010 –) though it does not indicate if 
any of the e-cigarette users quit smoking abruptly. Also the evidence is provided by three cross-
sectional surveys (Etter 2011 +, Etter 2011 +, Foulds 2011 –, Heavner 2010 –Heavner 2010 –) in 
which participants were possibly e-cigarette enthusiasts, particularly Foulds 2011 –. 
5. DISCUSSION 
A variety of settings, interventions and outcomes were studied, which together with a lack of high 
quality studies specifically investigating the long term use of nicotine containing products (NCPs) 
beyond 12 months in former smokers made it difficult to summarise the evidence relating to long term 
use of NCPs. Also some studies reported data related to NRT purchases or prescription refills rather 
than on actual use of NRT. The motivation of participants across the studies varied and in many cases 
was not reported. 
 Of the 15 included studies, ten had a primary focus on the use of NCPs (Etter 2009 +, Etter 2011 +, 
Foulds 2011 −, Hajek 2007 +, Heavner 2010 − , Hughes 2004 −, Johnson 1991 −, Johnson 1992 −, 
Shetty 2010 −, Shiffman 2003 −). Of these studies only Hajek 2007 + had 12 month follow-up data 
specifically concerned with long term NRT use in former smokers and provided details of the NRT 
provision but no information related to dose or amount. Hajek 2007 + was a prospective cohort study, 
Shetty 2010 – was an uncontrolled before and after and the others were cross-sectional surveys (Etter 
2009 +, Etter 2011 +, Foulds 2011 −,Heavner 2010 − , Hughes 2004 −, Johnson 1991 −, Johnson 1992 
−, Shiffman 2003 −).  
Overall there were three studies graded as high quality ++ (Blondal 1999 ++, LHS ++ [Bjornson-Benson 
1993; Murray 1996; Nides 1995], Sutherland 1992). Only three studies were conducted in the UK, 
Hajek 2007 +, Shetty 2010 – and Sutherland 1992 ++. Hajek 2007 + and Sutherland 1992 ++ were 
conducted in a smokers’ clinic and Shetty 2010 – within a medium secure hospital.  
This rapid review provides evidence that some smokers who quit smoking continue to use NRT 
products beyond the recommended period though overall this use is within recommended dosage 
limits. The evidence also suggests that baseline nicotine dependence is a predictor of long term NRT 
use. 
The evidence identified indicates that some users of e-cigarettes do use them for 12 months or longer 
but it is not clear if all users of e-cigarettes use them as a complete replacement for cigarettes. 
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ABBREVIATIONS  
 
BMI Body mass index 
BNF British National Formulary 
C  Control group 
CI Confidence interval 
CO  Carbon monoxide 
CPD  Cigarettes per day 
CSS Cross-sectional survey 
E-cigarette Electronic cigarette 
FTND Fagerstrom Test of Nicotine Dependence 
HMO Health maintenance organization  
I  Intervention group 
ITT Intention to treat  
LHS Lung Health Study 
MANOVA Multiple analysis of variance 
MHRA Medicines and Healthcare products Regulatory Agency 
NCP Nicotine containing product 
NICE  National Institute for Health and Clinical Excellence 
NRT  Nicotine replacement therapy 
OR   Odds ratio 
OTC Over the counter 
PC Prospective cohort 
RCP Royal College of Physicians 
RCT  Randomised controlled trial 
SI Special intervention 
THR Tobacco harm reduction 
UBA Uncontrolled before and after study 
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1. INTRODUCTION 
1.1. Background 
NICE requested a further evidence review to accompany a series of reviews to support the 
development of tobacco harm reduction (THR) guidance. This rapid review investigated the long 
term use of non-tobacco nicotine containing products (NCPs) in individuals who have attempted to 
quit smoking abruptly rather than via THR approaches.  Long term use of nicotine replacement 
therapy (NRT) has previously been identified as a potential issue in treating nicotine addiction in 
smokers (Hughes, 1998; RCP, 2000). 
For the purposes of this review ‘non-tobacco nicotine containing products’ were defined as NRT 
and ‘electronic nicotine delivery systems’ (sometimes known as ‘electronic cigarettes’ or ‘e-
cigarettes’) and topical gels. NRT is available in the following formulations: chewing gum, 
transdermal patches, inhalers, microtabs, mouth/nasal sprays and lozenges.  
Evidence for individuals who used NCPs long term following THR approaches (cut down to quit 
or long term harm reduction) would have been identified in the two previous THR effectiveness 
reviews.  
It was agreed that a full systematic review was not required but that the SURE team would 
examine studies that were identified through searching for the four THR reviews for any data on 
long term NCP use following an attempt of abrupt cessation; as well as employing snowballing 
techniques to identify other relevant studies concerned with the long term use of NCPs that were 
not identified in the production of the THR reviews. 
1.2. Aim of the review 
To identify and summarise evidence relating to the long term use of NCPs at or longer than 12 
months among abrupt quitters. 
1.3. Research questions 
Information was collected on the following: 
1. Length of time of using NCP 
2. Pattern of NCP use i.e. type of NCP, amount, frequency, reason for use 
3. Demographics of long term users e.g. gender, ethnicity, social determinants 
4. Predictors of long term use 
5. Purchase patterns 
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2. METHODS 
2.1. Literature search 
A search was conducted of the Reference Manager databases constructed from the 
comprehensive literature searches for all three reviews on effectiveness of tobacco harm 
reduction approaches and the barriers and facilitators to their implementation (which included 
smoking cessation search terms), as well as the database for the review: safety, risk and 
pharmacokinetics profiles of tobacco harm reduction technologies (Jones, 2011).1
NCP terms: 
 The search 
string sets listed below were combined with ‘AND’ and used to search within title, abstract and 
keywords (Reference Manager automatically searches for plurals). To be consistent with the three 
previous reviews, research conducted from 1990 was considered. 
{nicotine patch} OR {nicotine gum} OR {nicotine inhaler} OR {nicotine therapy} OR {nicotine replace} 
OR {nicotine lozenge} OR {nicotine tablet} OR {nicotine microtab} OR {nicotine nasal spray} OR 
{nicotine spray} OR {nicotine delivery} OR {nicotine gel} OR {nicotine pastille} OR {NRT} OR {e-cig} 
OR {electronic cigarette} OR {ecig} OR {Intellcig} OR {vaping} OR {vaporiser} OR {vaporizer} OR 
{cigarette substitut} OR {THR product} OR {nicotine containing product} OR {NCP} OR {Nicorette} 
OR {Nicorette} OR {Nicotinell} OR {Niconil} OR {NiQuitin} OR {Polacrilex} OR {Habitrol} OR 
{Nicabate} OR {NicoDerm} OR {Nicotex} OR {Nicotrol} OR {ProStep} OR {Quickmist} OR {Stoppers} 
OR {Commit lozenge} OR {nicotine pharmacotherapy} OR {Stubit} OR {super-25} 
Long term use terms: 
{long term use} OR {continued use} OR {continuous use} OR {extended use} OR {ever use} OR 
{longer duration} OR {usage pattern} OR {persistent use} OR {12 month} OR {18 month} OR {24 
month} OR {36 month} OR {12-month} OR {18-month} OR {24-month} OR {36-month} OR {year} OR 
{pattern of use} OR {purchase pattern} 
2.1.1. Additional searches 
The first authors of the included publications of the three THR reviews were contacted in 
February 2012 to request information on additional published studies. 
The reference lists of all the included publications were checked for additional studies. 
Publications from large scale smoking cessation studies and long term observational studies 
on smoking behaviours e.g. Lung Health Study (LHS), Smoking Toolkit study, ITC Four 
Country Survey were identified and considered for inclusion. 
Alerts received from ASH Scotland and Global link were screened and a request was posted 
to Global link for information relevant to this review. Note:  These alerts identify all types of 
publication, including grey literature. 
The contents pages of the ‘top’ journals for the three previous reviews as well as for this 
current review (i.e. the journals that contain the greatest number of papers that meet 
inclusion criteria) were hand searched from September 2011 to March 2012. These journals 
were: Addiction; Addictive Behaviors; Nicotine & Tobacco Research; Preventive Medicine 
and Tobacco Control. 
                                                          
1 The original search from which the Reference Manager databases were constructed included 48 databases and web sites to 
identify a wide range of publications, including grey literature. Searches were for studies published in the English language between 
1990 and 2011.Update searches were conducted in November 2011 and January 2012. 
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2.2. Inclusion and exclusion criteria 
Inclusion: 
• Long term use (≥12 months) in 
those attempting to quit abruptly 
• Published intervention, 
longitudinal and cross-sectional 
studies 
• Purchase patterns i.e. information 
relating to  OTC and online 
purchases 
 
 
 
Exclusion: 
• Adverse effects (covered by 
Review 1) 
• Addiction 
• Interventions to aid NCP reduction 
or cessation 
• Long term use of NCP when used 
in combination with other smoking 
cessation preparations e.g. 
Varenicline or Buproprion or with 
alternative or complementary 
therapies e.g. hypnotherapy or 
acupuncture. 
• Use in pregnant women 
  
Where interventions of interest were compared to or used in combination with excluded 
interventions, studies were only included if the data for the interventions of interest could be 
disaggregated. Where disaggregation was not possible they were excluded. 
2.3. Study selection 
Publications that were identified by title as being clearly irrelevant were excluded. Titles and 
abstracts were screened by HM using the inclusion/exclusion parameters, if in doubt the 
publication was included. Only publications that explicitly stated in the abstract that they were 
concerned with long term use or contained other relevant information of interest or stated that 
had follow-up data of 12 months or longer were retained for full text screening. If an abstract only 
stated follow-up data at 12 months without data concerned with long term use or other relevant 
information of interest then it was excluded. Publications were also retained which had been 
identified for the previous three reviews as containing long term use data. Full publication 
screening was undertaken by HM and exclusions were checked by FM. Publications excluded at full 
text were retained with reasons for exclusion.   
2.4. Quality assessment  
Quality assessment was conducted by each data extractor (FM, HM, AW or SW) and checked by 
another member of the review team using the GATE checklists for quantitative studies [NICE 
2009]. Any disagreement was resolved by discussion. The review team assessed each study’s 
internal and external validity; where external validity measured how far the findings of the study 
might be generalised beyond the participants to a wider population from which the participants 
were drawn (e.g. from one community setting in the US to all US communities) but not to other 
populations. Given the inherent problems of bias and confounding associated with the design of 
cross sectional surveys, these studies were rated only as + or – and summary scores only are 
presented. All ratings are included in the evidence tables.  In addition, Appendix B and C provide a 
summary of the quality ratings for each element of the included studies that were assessed.  
2.5. Applicability to the UK 
Based on advice from members of the Expert Advisory Group for the previous three reviews, it was 
agreed that research from settings where the smoking reduction and cessation programmes are 
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sufficiently similar to those in the UK (including Spain, Norway, Denmark, Australia and New 
Zealand) would be assessed as having high applicability to the UK. 
2.6. Data extraction 
Data were extracted by a member of the review team (FM, HM, AW or SW) and checked by 
another, in accordance with Appendix K of the NICE Public Health Methods Manual. These are 
presented in the Evidence Tables with study characteristics, quality scores and outcome measures 
reported by the authors (with associated 95% confidence intervals (CI) and p-values where 
available). 
2.7. Data synthesis 
The key findings of evidence have been summarised in concise narrative summaries and are 
supported by evidence tables (Appendix A).  
The strength of evidence assessment in the evidence statements is based on the most recent 
GRADE guidance (Guyatt 2011). The definitions used are broadly defined as follows with potential 
for moving up or down a grade as summarised in the guidance (Guyatt 2011): 
GRADE low, very low quality  = weak evidence (e.g. before and after studies graded –) 
GRADE moderate quality  = moderate evidence (e.g. RCTs/quasi RCTs graded +) 
GRADE high quality   = strong evidence (e.g.  RCTs graded ++) 
Rapid review for NICE: long term use of non-tobacco nicotine containing products in individuals who have quit smoking abruptly 
 
 
12  
 
3. RESULTS 
3.1. Search Results 
The search methods identified 888 citations of which 119 were excluded by title as clearly 
irrelevant. Of the remaining 769 citations that were screened by title and abstract 676 were 
excluded and 93 were considered for full text screening. An additional 8 publications were 
identified from reference list checking of included papers. A total of 101 papers were screened in 
full text which resulted in the exclusion of 83 and the inclusion of 18 papers. A full list of excluded 
papers for this review, with reasons for exclusion, is provided in Appendix F. 
A total of 18 papers were included in the review, comprising of 15 studies. See Table 1 (pp. 10-12) 
for a brief summary of the studies. Full details are provided in the Evidence Tables (Appendix A).  
 
 
  
1038 records identified through 
searching of RM database across 
reviews 1- 4  
888 records after duplicates removed  
Title abstract screening of 769 
records 
676 records excluded 
101 full-text papers assessed 
for eligibility 
83 of full-text papers 
excluded 
18 of full-text papers included  
250 records suggested by authors. After 
manual searching for relevancy and 
duplication 14 were identified as potentially 
relevant 
119 excluded as clearly 
irrelevant 
8 from reference list 
checking of included 
papers 
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3.2. Quality and applicability of studies 
Overall, the quality of the 15 included studies varied. Whilst the three RCTs (Blondal 1999 ++, LHS 
++ [Bjornson-Benson 1993; Murray 1996; Nides 1995], Sutherland 1992 ++) were all assessed as 
being of high quality, only four of the remaining studies, two prospective cohort studies (Hajek 
2007 +, Schneider 2003 +) and two of the eight cross-sectional surveys  (Etter 2009 +, Etter 2011 
+), were rated as moderate quality.  
Three studies were from the UK (Hajek 2007 +, Shetty 2010 −, Sutherland 1992 ++) and these 
were in specific populations with Shetty 2010 – having a small sample size. Two studies were 
conducted in Europe (Blondal 1999 ++, Schneider 2003 +). Seven studies were conducted in 
Canada and the USA (Foulds 2011 −, Hatsukami 1993 −, Hughes 2004 −, Johnson 1991 & 1992 −, 
LHS ++ [Bjornson-Benson 1993; Murray 1996; Nides 1995], Shiffman 2003 −). Three were internet 
surveys (Etter 2009 +, Etter 2011 +, Heavner 2010 −) conducted in English with Etter 2011 + also in 
French. 
Of the 15 studies, 5 were in a community setting (Blondal 1999 ++, Hatsukami 1993 −, Hughes 
2004 −, LHS ++ [Bjornson-Benson 1993; Murray 1996; Nides 1995], Shiffman 2003 −). Foulds 2011 
– at an electronic cigarette enthusiast meeting, Etter 2009 +, Etter 2011 +, Heavner 2010 – were 
internet surveys, Hajek 2007 +, Schneider 2003 + and Sutherland 1992 ++ in a smoker’s clinic or 
smoking cessation unit, Johnson 1991 − and Johnson 1992 – within a health maintenance 
organization and Shetty 2010 – was conducted in a medium secure hospital. 
3.3. Outcomes 
Data were extracted for all NCP use of 12 months or longer related to length of time used, type of 
NCP, amount, frequency, reason for use, demographics of long term users, predictors of long term 
use and purchase patterns of long term users.
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Table 1: Brief summary of included studies  
* Studies are complex and this table can only give a flavour of each intervention. See Appendix A for more detailed summaries. 
Author and 
Year  
Location and 
setting2
Population 
   
Study outline Internal validity3 
Blondal 1999 
RCT 
Iceland + 
Community 
237 adults 
1% attrition 
Nicotine patch for 5 months (tapering from 15 mg for 3 months, 10 mg 
at month 4 to 5 mg at month 5) with nicotine nasal spray 
(0.5mg/nostril) for 1 year. CO verified abstinence to 12 months and 5 
years. Participants likely to motivated to quit since responders to 
adverts in local papers and on television. 
++  High quality study other than self-reported 
outcomes only for NRT use (though would be 
difficult to confirm). Two authors were 
employed by, and one consulted for, Pharmacia 
and Upjohn. Pharmacia and Upjohn measured 
the cotinine concentrations but the trial is 
described as double blind. 
Etter 2009 
Cross-
sectional 
survey 
Internet + 
English survey 
on a Swiss 
website 
526 adults Questionnaire in English on the StopTabac.ch web site with a link from 
other smoking cessation web sites.  After 30 days, NRT gum users who 
agreed and indicated an email address received a message asking 
whether they were still using NRT, their length of NRT use and their 
level of craving for NRT gum. Participants were self selected visitors to 
tobacco cessation web site.  
+    Self-selected sample. Unlikely to be 
representative of all gum users. Self-reported 
data.  Mean duration of gum use was more than 
2 years but authors described long term use as > 
3 months.  No separate data for 12 months plus.  
Authors received financial support from Pfizer 
and Novartis, gum producers. 
Etter 2011 
Cross-
sectional 
survey 
Internet − 
Website 
available in 
English and 
French 
languages 
3,587 adults Survey assessed the profile, utilization patterns, satisfaction and 
perceived effects among users of electronic cigarettes.  Motivation of 
participants not reported. 
+    Predominantly self-selected users of web sites 
dedicated to e-cigs. Self-reported data. 
 
Foulds 2011 
Cross-
sectional 
survey 
USA − 
Meeting of e-
cigarette 
enthusiasts 
104 adults Cross-sectional survey aimed to identify the e-cig products used by 
experienced e-cig users, their pattern of e-cig use and the impact on 
tobacco use. Motivated e-cigarette users. 
− Self-selecting sample of e-cig users so potential 
for bias. Small sample so not likely to be 
representative. 
                                                          
2 The symbols (++ + –) in this column refer to the external validity; where ++ indicates an intervention that is applicable to all members of the population for which the study was designed. As external 
validity decreases, it is measured by + and then –. 
3 The symbols in this column provide a summary rating for quality; where ++ indicates that the study has been conducted so as to minimise risk of bias. As quality decreases/risk of bias increases, it is 
measured by + and then –.  
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Hajek 2007 
Prospective 
cohort 
UK ++ 
Smokers’ clinic 
1,518 adults NRT prescription for attendees to a smokers' clinic. 3-month 
programme of treatment combined medication (with advice to use for 
≤3 months) and behavioural support (UK Stop Smoking Service).  Until 
April 2001 NRT was sold to participants for ≤one year at a cost of $174
+    Self-report only, small sample for assessing 
effect of cost. No data on consumption of NRT. 
 
per week. From April 2001 prescription was free for ≤one year 
contingent on continuing abstinence (free prescription for circa 70% of 
participants and $11 per week for others). Follow-up to 12 months. 
Participants likely to be motivated since attendees at a cessation clinic. 
Hatsukami 
1992 
Uncontrolled 
before and 
after 
USA + 
Community 
71 adults 
11% attrition 
Use of 2mg gum for 1 or 3 month, attendance at weekly individual 
sessions. Each participant provided $50 deposit to be returned if they 
were abstinent at end of treatment. Participants in 1-month group who 
complied with study procedures paid $50; those in 3-month group paid 
$150. Follow-up to 12 months. Participants motivated to quit. 
- Small sample and no biochemical verification at 
follow-up. Lack of control. 3 month group had 
more frequent contact than the 1 month group. 
Heavner 2010 
Cross-
sectional 
survey 
Internet − 
Respondents 
predominantly 
from USA and 
Europe 
270 adults Survey assessed e-cigarette users' patterns of cigarette and e-cigarette 
usage and smoking cessation attempts, and compared health status and 
smoking-attributable symptoms between people who completely 
switched from smoking to e-cigarettes, and those who supplemented 
cigarette smoking with e-cigarette usage. Highly motivated e-cigarette 
users. 
- Highly motivated and passionate e-cigarette 
users, likely leading to a biased sample.  Some of 
the questions were imprecise and some answers 
difficult to interpret.  Self-report only. One 
author is Director of E Cigarette Direct, who 
initiated and conducted the research. 
Hughes 2004 
Cross-
sectional 
survey 
USA ++ 
Community  
Study 1: 266 
adults 
Study 2: 100 
adults 
Survey to estimate the misuse of and dependence on over-the-counter 
nicotine gum in a volunteer sample, including patterns of use. Mixed 
motivations. 
- Volunteer samples, so results may not be 
applicable (often have higher prevalence and 
more severe forms of a disorder than 
population-based samples). Single cross-
sectional surveys tending to oversample those 
with chronic conditions. Possible recruitment 
bias toward those addicted to NRT.  
Johnson 1991 
Cross-
sectional 
survey 
USA/Canada + 
Health 
Maintenance 
Organisation 
1,970 adults Cross-sectional survey to describe the extent of nicotine chewing gum 
use among health maintenance organization members, the 
characteristics of prescribers and users, and the patterns of gum use 
over a two-year period. 
-     No data provided on actual number of users and 
length of continuous use or how many users and 
gum dose. No data collected on smoking 
behaviour. 
Johnson 1992 USA/Canada + 612 gum users Cross-sectional survey to assess nicotine gum use when prescribed in a - Random sampling and high response rate but 
                                                          
4 Note: amounts in US$ because paper published in US-based journal 
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Cross-
sectional 
survey 
Health 
Maintenance 
Organisation 
86.4% 
response rate 
non-research, routine outpatient setting including patterns of use.  
Motivation of participants not reported. 
caveats associated with cross-sectional survey 
Lung Health 
Study: 
Bjornson-
Benson 1993; 
Murray 1996; 
Nides 1995 
RCT 
USA/Canada ++ 
Community 
5,887 adults 
10% attrition 
of SI group 
Special intervention with either bronchodilator (SI-A) or placebo (SI-P) 
inhaler plus a multisession behavioural program. Additionally, smoking 
cessation maintenance activities, 4-monthly scheduled clinic visits plus 
2mg/piece nicotine gum after quitting. Follow-up to five years. 
Participants were willing to consider cessation. 
++ Self-report of gum use. Large study with specific 
objective of evaluating the efficacy of early 
intervention for chronic obstructive pulmonary 
disease among cigarette smokers who have mild to 
moderate impairment in pulmonary function. Long 
term use of NRT was not a primary focus, so 
difficult to extract specific data. 
Schneider 
2003 
Prospective 
cohort 
Switzerland + 
Hospital based 
smoking 
cessation unit 
92 adults 
11% attrition 
Nicotine nasal spray provided for up to 18 months. Usage measured by 
MDILog device attached to spray. Self-reported continuous abstinence 
validated by expired CO measured up to 24 months. Highly motivated 
participants. 
+    Small sample 
Shetty 2010 
Uncontrolled 
before and 
after 
UK + 
Medium secure 
hospital 
50 male adults Retrospective review of the effect of a trust wide smoke-free policy on 
changes in behaviour, incidents and prescribing. Motivation of 
participants not reported. 
- Small sample, retrospective analysis, smoking 
practices outside of hospital would have been 
useful. 
Shiffman 
2003 
Cross-
sectional 
survey 
USA + 
Community  
2,960 
households 
Cross-sectional survey to estimate the incidence of persistent use of 
OTC nicotine gum and patch for periods of >3 months, ≥ 6 months, ≥ 12 
months and ≥ 24 months.  No information on motivation of participants. 
- No actual use data collected i.e. NRT products 
may be purchased but not used. Household data 
rather than individual. No data on smoking 
status or behaviour. No data on physician 
consultations. Purchase patterns may shift with 
time as OTC NRT becomes more established. 
Sutherland 
1992/ 
Stapleton 
1998 
RCT 
UK ++ 
Hospital 
smokers’ clinic 
227 adults 
4.5% attrition 
Nicotine nasal spray 1mg/dose with maximum 5 doses/hour and 40 
doses/day. Recommended duration of use = 3 months. No formal dose 
reduction regimen. Biochemically validated complete abstinence 
measured up to 12 months. Participants were motivated to stop 
smoking. 
++    Well conducted study 
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4. FINDINGS 
Three studies collected data on a range of NRT products (Hajek 2007 +, Shetty 2010 −, Shiffman 2003 
−). Six studies examined nicotine gum (Etter 2009 +, Hatsukami 1993 −, Hughes 2004 −, Johnson 1991 
−, Johnson 1992 −, LHS ++ [Bjornson-Benson 1993; Murray 1996; Nides 1995]). Two explored the effect 
of nicotine nasal spray (Schneider 2003 +, Sutherland 1992 ++). One (Blondal 1999 ++) looked at the 
effect of nicotine patch with nicotine nasal spray. Three studies explored the use of electronic 
cigarettes (Etter 2011 +, Foulds 2011 −, Heavner 2010 −). Ten of the included studies (Etter 2009 +, 
Etter 2011 +, Foulds 2011 −, Hajek 2007 +, Heavner 2010 − , Hughes 2004 −, Johnson 1991 −, Johnson 
1992 −, Shetty 2010 −, Shiffman 2003 −) specifically explored the use of NRT products or electronic 
cigarettes with the remainder providing usage data as additional information to their primary outcomes 
of interest. 
4.1. Nicotine Gum 
Study Background 
Etter 2009 + (cross-sectional survey) assessed the use of and dependence on nicotine gum in 
former smokers and compared short-term users (3 months or less) to long-term users (greater 
than 3 months). The survey was conducted with a self-selected sample which might not be 
representative of all users.  Information was not provided regarding the manner in which gum was 
obtained. Of those using gum for greater than 3 months 82.8% (250/302) agreed to the statement 
“because I am addicted to the nicotine gum” as being either very or extremely true. Those using 
gum for greater than 3 months were using a median nicotine dose of 24mg/day. 
Hajek 2007 + (prospective cohort) assessed the effect of long-term use of different NRT products 
in smokers attending routine smoking cessation treatment and examined the effect of NRT cost on 
its long term use. Participants were allowed to select their preferred NRT product and advised to 
use it in accordance with the manufacturer's instructions for up to 3 months. Information 
regarding the dose and amount of NRT that was used was not provided. They were seen weekly 
over 6 weeks with the last session scheduled at 4 weeks after their quit date. Patients continued to 
receive NRT as needed via their doctors or pharmacists, collecting prescription forms at the clinic, 
or buying NRT over-the-counter. The clinic treatment was free though the NRT products had 
varying levels of cost. Until April 2001, NRT was sold to participants for up to 1 year at a cost of 
$17 per 1-week supply (during this time participants receiving free prescriptions were entitled to 
one or four weeks free NRT). From April 2001 NRT was provided ‘on prescription’ for up to 1 year, 
contingent on remaining abstinent from smoking. Approximately 70% of clinic patients were 
entitled to receive NRT free of charge, while the rest paid a prescription charge of US $11 for each 
1-week supply (amounts in US$ because paper published in US-based journal). 
Hatsukami 1993 – (uncontrolled before and after) examined whether longer duration of nicotine 
gum use in smokers promoted dependence on nicotine gum. Of the 128 participants entering the 
study only 71 complied with all study procedures and were successful at quitting smoking. 
Participants were randomly assigned to use 2mg nicotine gum for either one month or three 
months. Participants’ motivation to quit smoking was self-rated as seven or greater on a 10-point 
scale. Gum was provided free of charge and participants were required to attend weekly individual 
sessions while being treated with nicotine gum. Participants had to provide a $50 deposit to be 
returned if they had quit smoking at the end of treatment. Those in the one month group who 
complied with study procedures were paid $50 and those in the three month group $150.  
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Hughes 2004 – (cross-sectional survey) estimated the misuse of and dependence on OTC nicotine 
gum in a volunteer sample in two separate studies. The recruitment strategy of both may have 
resulted in a biased sample. For study 1 most participants were recruited via newspaper ads 
indicating that current nicotine gum users were sought for a telephone survey and would be 
reimbursed with $25 for their time. Study 2 also recruited via newspaper ads stating “Are you 
addicted to nicotine gum? If so we would like to interview you as part of a university study. 
Reimbursement of $25 for one telephone interview”. For both studies participants were required 
to have a history of smoking. 
Johnson 1991 – and Johnson 1992 – (both cross-sectional surveys) described the use of nicotine 
chewing gum among members of a health maintenance organization. Johnson 1991 – only 
provided prescription data and did not provide data on smoking status, reason for use, nicotine 
dose or the manner in which gum was provided i.e. if encouraged by health professionals or 
individual choice. Johnson 1992 – focussed on 498 nicotine gum users who reported being regular 
smokers of cigarettes during the previous 3 years. Many of the respondents (75%, numbers not 
provided) reported that they had initially requested nicotine gum from their physician, dentist or 
nurse, as opposed to having their provider encourage them to try the gum. The dose of the 
nicotine gum was not provided. Only 5% of gum users attended a structured behavioural 
treatment program while using the gum. Over half, 56.6% (282/498), of the gum users in the total 
sample reported that they had used nicotine gum to help them “cut down on the amount smoked 
each day”.  
The primary  objective of the LHS ++ (RCT)[Bjornson-Benson 1993; Murray 1996; Nides 1995] was 
to evaluate the efficacy of early intervention for chronic obstructive pulmonary disease among 
cigarette smokers who have mild to moderate impairment in pulmonary outcomes and provided 
an opportunity to investigate other outcomes. Participants to the intervention group were offered, 
either on an individual or group basis, a 12 week stop-smoking program and were encouraged to 
use nicotine gum throughout the 12 week program. Nicotine gum (2mg dose) was provided free of 
charge at each meeting of the initial cessation program and then at two week intervals. Careful 
instruction was provided and the recommendation that 10-12 pieces of gum were used per day. 
Gum use was limited to 6 months; extended use was approved when necessary. A maintenance 
program, including various support activities, was also offered. The publications from the LHS ++ 
included in this review focused on the following: patterns of nicotine-gum use and smoking 
cessation in the first year of the LHS (Bjornson-Benson 1993); cardiovascular conditions and other 
side effects associated with the use of 2mg nicotine polacrilex (Murray 1996); predictors of initial 
smoking cessation and relapse during the first 2 years of the LHS (Nides 1995). 
Shiffman 2003 – (cross-sectional survey) estimated the incidence of persistent use of OTC nicotine 
gum and patch for periods up to and beyond 24 months. All OTC NRT purchases made by a panel 
of households were tracked. These included: doses of 2 and 4mg nicotine gum; 7, 11, 14, 15, 21 
and 22mg patches; various flavours; colours and package sizes. Data was not collected regarding 
actual use, smoking behaviour or physician consultations. 
Length of time of using gum 
Although Blondal 1999 ++ evaluated the efficacy of using a nicotine patch for five months with a 
nicotine nasal spray for one year it was observed that at five years, two of the 22 participants in 
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the intervention group (9.1%) were occasionally using nicotine chewing gum; their smoking status 
was not reported or how nicotine gum was obtained. 
The LHS ++ (Bjornson-Benson 1993) observed that at 12 months 33.6% of 1069 sustained non-
smokers, 19.2% of 2071 continuing smokers and 54.5% of 595 intermittent smokers were using 
nicotine gum. Intermittent non-smokers (those that had a non-smoking status at the time of the 
follow-up visit but who reported a smoking pattern that included at least one month each of 
smoking and non-smoking in the eight months prior to the 12 month visit) were more likely to be 
using gum than any other group, p<0.001. 
LHS ++ [Murray 1996]) observed at five years that 14% of former smokers and 5% of participants 
who were unsuccessful at quitting smoking were using gum. 
Hajek 2007 + reported that at 12 months 13% (10/76) of long term users of NRT who had quit 
smoking were using nicotine gum. 
Hatsukami 1993 – identified that after 12 months since quitting smoking 8% (5/63) of participants 
reported regular gum use since the last follow-up with one participant still continuing to use gum. 
Etter 2009 + reported that of former smokers responding  to an internet survey, 57% (302/526) 
had used gum for more than three months with a median of 730 days of use. 
In Hughes 2004 –, the first of two cross-sectional surveys (Study 1) reported that 46% (122/266) of 
the sample had used the gum for longer than the recommended three months. Among long term 
users (i.e. use of gum ≥90 days), the median number of days of use was 242 (25th-75th
Johnson 1991 – reported that of the 11% (216/1970) of nicotine gum users with four or more 
prescriptions, 90% (195/216) had periods of continuous use (218 periods in total).  Of those 
continuous use periods, 30% (66/218) were longer than six months, with the longest period being 
19 months.  A period of continuous use was considered to be time between refills where gum 
could have been used at a consistent average daily dose (eight or more pieces of gum/day). 
Smoking status was not reported. In a similar study (Johnson 1992 –), 4.4% (19/428) of 
participants reported using gum for between one and two years and 2.8% (12/428) reported using 
gum for more than 2 years. The smoking status of these users was not reported though over half, 
56.6% (282/498), of the gum users in the total sample reported that they had used nicotine gum to 
help them “cut down on the amount smoked each day”. 
 percentile 
158-409). For the second cross-sectional survey (study 2), in which participants had self-reported 
addiction to nicotine gum, the median duration of gum use was 32 months (95% CI 15, 50) and 
98% (98/100) of participants had used gum for at least 3 months. In study one 35% (CI 29%, 41%) 
of all gum users were smoking and using gum concurrently and in study two 12% (CI 6%, 23%) 
were concurrent gum and cigarette users. 
Pattern of long term gum use 
Dosage: 
The LHS ++ [Bjornson-Benson 1993] observed at 12 months that sustained non-smokers were 
using an average of 8.2 pieces of nicotine gum per day (average total of 16.4mg nicotine/day). 
Average pieces of gum/day were significantly different for intermittent smokers and intermittent 
non-smokers, 7.5 (total of 15mg nicotine/day) and 9.7 (total of 19.4mg nicotine/day) respectively 
(p<0.001). (Intermittent non-smokers had a non-smoking status at the time of the follow-up visit 
but overall reported a smoking pattern that included at least 1 month each of smoking and non-
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smoking in the 8 months prior to the 12 month visit.) Additionally (LHS ++ [Murray 1996]), among 
sustained non-smokers from the intervention groups, the level of gum use trended upwards over 
the course of the study (4-60 months) to 10 pieces per day (total of 20mg nicotine/day). 
In the first cross-sectional survey (Study 1) in Hughes 2004 –, the mean daily dose of nicotine 
obtained by long term users of gum (i.e. use of gum for at least 90 days) was 16mg/day. In Study 2, 
in which participants had self-reported addiction to nicotine gum, the mean daily dose of nicotine 
obtained by gum users was 30mg/day with the median duration of gum use being 32 months (95% 
CI 15, 50). In both studies not all gum users had quit smoking. 
In Johnson 1991 –, where gum was used for a period of 12-18 months, there were 10 periods of 
continuous use that involved less than eight pieces of gum per day (either less than 16 or 
32mg/day assuming that either 2 or 4mg of nicotine/piece) and seven that involved eight or more 
pieces per day (at least 16 or 32mg/day assuming that either 2 or 4mg of nicotine /piece). For gum 
use over eighteen months, there were two periods of continuous use involving less than eight 
pieces of gum per day and four involving eight or more pieces per day. A period of continuous use 
was considered to be time between refills where gum could have been used at a consistent 
average daily dose (eight or more pieces of gum/day). The study identified that 0.3% of users 
consumed 50-99 boxes (one box=96 pieces of gum) over two years. Two users consumed more 
than 100 boxes (9600 pieces of gum) during this period, although it is not clear whether this was 
for personal use or if gum had been shared with another user. The dose of the gum used is not 
provided but assumed that either 2 or 4 mg/piece. 
Reason for use: 
At the time of the Study 1 survey in Hughes 2004 –, most long-term users (i.e. use of gum for at 
least 90 days), 72% (CI 63%, 79%), were using gum to stop smoking or prevent relapse, 8% (CI 4%, 
14%) for non-cessation reasons and 20% (CI 14%, 29%) spontaneously volunteered addiction to 
nicotine gum as the reason for their continued use. In the study 2 survey, in which participants had 
self-reported addiction to nicotine gum, a total of 92% (CI 87%,97%) of all users purchased gum 
initially to stop smoking or prevent relapse, 2% (CI 0%, 5%) to reduce smoking and 4% (CI 0%, 8%) 
to avoid restrictions. 65% (CI 55%, 74%) reported inability to control use, 75% (CI 66%, 84%) 
reported difficulty stopping, 61% (CI 46%, 76%) reported that stopping gum was extremely 
difficult, compared to 59%  (44%, 74%) who reported that stopping cigarettes was extremely 
difficult. In both studies not all gum users had quit smoking. 
Demographics of long term gum users 
The LHS ++ identified that at 12 months, of those who had quit smoking, women were more likely 
than men to use nicotine gum (p<0.0001) but no differences were found for the amount used 
(Bjornson-Benson 1993).  Of sustained non-smokers at 24 months (numbers not provided), 28% of 
women and 19% of men reported current use of nicotine gum (Nides 1995). 
The study 1 survey in Hughes 2004 – identified that those who were older were more likely to be 
long term users (p<.0001). 
Predictors related to long term gum use 
The LHS ++ [Bjornson-Benson 1993]) identified that for sustained non-smokers (n=1069) at 12 
months, gum use was significantly associated with being female (p=0.002); having a lower body 
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mass index (p=0.028); previous history of gum use (p=0.0001) or quit attempts (p=0.004) and 
nicotine dependence (seven variables assessed with p=0.0001-0.038). Only nicotine dependence 
variables were associated with using more pieces per day. 
The study 1 survey in Hughes 2004 – identified that those who had smoked for longer more likely 
to be long term users (p<.0001). 
Purchase patterns of long term gum users 
Shiffman 2003 – reported that 1% (8/805) of households purchased gum for 12 months or more 
and 0.4% (3/805) for 24 months or more. In households with persistent gum purchase (allowing 
for a 1 month gap between purchases), 2.8% (23/805) purchased gum for 12 months or more and 
1% (8/805) for 24 months or more. Only purchase data was collected. 
4.2. Nicotine Patch 
Study Background 
Hajek 2007 + (prospective cohort) assessed the effect of long-term use of different NRT products 
in smokers attending routine smoking cessation treatment and examined the effect of NRT cost on 
its long term use. Participants were allowed to select their preferred NRT product and advised to 
use it in accordance with the manufacturer's instructions for up to 3 months. Information 
regarding the dose and amount of NRT that was used was not provided. They were seen weekly 
over 6 weeks with the last session scheduled at 4 weeks after their quit date. Patients continued to 
receive NRT as needed via their doctors or pharmacists, collecting prescription forms at the clinic, 
or buying NRT over-the-counter. The clinic treatment was free though the NRT products had 
varying levels of cost. Until April 2001, NRT was sold to participants for up to 1 year at a cost of 
$17 per 1-week supply (during this time participants receiving free prescriptions were entitled to 
one or four weeks free NRT). From April 2001 NRT was provided ‘on prescription’ for up to 1 year, 
contingent on remaining abstinent from smoking. Approximately 70% of clinic patients were 
entitled to receive NRT free of charge, while the rest paid a prescription charge of US $11 for each 
1-week supply (amounts in US$ because paper published in US-based journal). 
Shiffman 2003 – (cross-sectional survey) estimated the incidence of persistent use of OTC nicotine 
gum and patch for periods up to and beyond 24 months. All OTC NRT purchases made by a panel 
of households were tracked. These included: doses of 2 and 4mg nicotine gum; 7, 11, 14, 15, 21 
and 22mg patches; various flavours; colours and package sizes. Data was not collected regarding 
actual use, smoking behaviour or physician consultations. 
Length of time of using patches 
Hajek 2007 + reported that at 12 months 20% (15/76) of long term users of NRT who had quit 
smoking were using nicotine patches. 
Pattern of long term patch use 
No studies were identified that reported this data. 
Demographics of long term patch users 
No studies were identified that reported this data. 
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Predictors related to long term patch use 
No studies were identified that reported this data. 
Purchase patterns of long term patch users: 
Shiffman 2003 – reported that 0.1% (2/2050) of households purchased patches for 12 months or 
longer and 0.05% (1/2050) for 24 months or longer. In households with persistent patch purchase 
(allowing for a one month gap) 0.4% (8/2050) purchased for 12 months or longer and 0.05% 
(1/2050) for 24 months or longer. Only purchase data was collected. 
4.3. Nicotine Nasal Spray 
Study Background 
Blondal 1999 ++ (RCT) evaluated the efficacy of using a nicotine patch for five months with a 
nicotine nasal spray for one year allowing a more flexible method of nicotine delivery. Recruited 
smokers received a baseline assessment 3-6 weeks before they were required to stop smoking, 
followed by an instructional meeting. Participants attended four supportive group meetings at 1, 
8, 15 and 22 days after stopping smoking. Nicotine patch was received for 5 months (tapering from 
15mg for 3 months, 10mg at month 4 to 5mg at month 5) with nasal spray (0.5mg/nostril) for 1 
year. 
Hajek 2007 + (prospective cohort) assessed the effect of long-term use of different NRT products 
in smokers attending routine smoking cessation treatment and examined the effect of NRT cost on 
its long term use. Participants were allowed to select their preferred NRT product and advised to 
use it in accordance with the manufacturer's instructions for up to 3 months. Information 
regarding the dose and amount of NRT that was used was not provided. They were seen weekly 
over 6 weeks with the last session scheduled at 4 weeks after their quit date. Patients continued to 
receive NRT as needed via their doctors or pharmacists, collecting prescription forms at the clinic, 
or buying NRT over-the-counter. The clinic treatment was free though the NRT products had 
varying levels of cost. Until April 2001, NRT was sold to participants for up to 1 year at a cost of 
$17 per 1-week supply (during this time participants receiving free prescriptions were entitled to 
one or four weeks free NRT). From April 2001 NRT was provided ‘on prescription’ for up to 1 year, 
contingent on remaining abstinent from smoking. Approximately 70% of clinic patients were 
entitled to receive NRT free of charge, while the rest paid a prescription charge of US $11 for each 
1-week supply (amounts in US$ because paper published in US-based journal). 
Schneider 2003 + (prospective cohort) evaluated the efficacy of prolonged administration (18 
months) of a nicotine nasal spray in a smoking cessation program and attempted to characterise 
the pattern of spray use with a specially developed electronic monitor in an effort to assess the 
factors associated with cessation success or failure. This was a small study sample of 92 
participants referred to a smoking cessation unit. Spray use was allowed ad libitum for 18 months 
with the advice to use as often as necessary for the first 4-6 months followed by only for 
occasional help. Only usual smoking cessation counselling was offered except if requested by the 
participant or clinician. A dose of the nicotine nasal spray consisted of two puffs (0.5mg/nostril) 
though as some participants only used one puff per dose analysis was done on number of puffs 
used. 
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Sutherland 1992 ++ (RCT) evaluated the efficacy of a nasal nicotine spray as an adjunct to group 
treatment for smoking cessation and the companion paper (Stapleton, 1998) reported on the long 
term follow up to estimate the impact of relapse after one year on effectiveness. A dose consisted 
of two sprays, one to each nostril (1mg of nicotine in total). Spray use was ad libitum but limited to 
5 doses per hour (total of 5mg of nicotine) and 40 doses per day (40mg of nicotine in total). An 
instruction leaflet was provided and the recommended duration of use was 3 months. No formal 
dose reduction regimen was provided. 
Length of time of using spray: 
Blondal 1999 ++ evaluated the efficacy of using a nicotine patch for five months with a nicotine 
nasal spray for one year. At 12 months, 32 participants in the intervention group had ceased 
smoking, of these 13% (4/32) were still using the nasal spray. In the placebo group 13 participants 
had ceased smoking; none of these were using the placebo nasal spray. 
Hajek 2007 + reported that at 12 months 23% (18/76) of long term users of NRT who had quit 
smoking were using spray. 
Schneider 2003 + found that among former smokers 50% (8/16) at 12 months and 42% (5/12) at 
18 months were still using a spray. Of the six participants considered partial successes (i.e. those 
who admitted occasional smoking but with a CO level less than 10 ppm and were willing to 
continue in the study) three were still using spray at 18 months. 
Sutherland 1992 ++ reported that none of the control participants who had given up smoking used 
the spray beyond six months. However, in the intervention group 43% (13/30) of former smokers 
were still using the spray at 12 months. A follow-up paper (Stapleton 1998) reported that of 33 
former smokers in the intervention group, 19 used the spray for one year and 14 for more than 
one year (range 1-39 weeks). 
Pattern of long term spray use 
Dosage: 
Blondal 1999 ++ evaluated the efficacy of using a nicotine patch for 5 months with a nicotine nasal 
spray for 1 year. At 12 months 13% (4/32) of former smokers were using nasal spray with a mean 
of 22 self-reported 1mg doses per day (22mg/day). These four former smokers had higher cotinine 
levels than baseline (131% of mean blood cotinine concentration at baseline). 
Schneider 2003 + nthat at 18 months one of the five former smokers still using the spray was using 
it above recommended levels (median of 94 puffs/day, approx. 47mg/day). Of the three users in 
the partial success group (i.e. those who admitted occasional smoking but with a CO level less than 
10 ppm and were willing to continue in the study) still using the spray, one was using 1-
15puffs/day (0.5mg-7.5mg/day), a second 16-30 puffs/day (8mg-15mg/day) and the third more 
than 30 puffs/day (median 33 puffs/day, approx. 16.5mg/day). A dose of the nicotine nasal spray 
consisted of two puffs (0.5mg/nostril) though as some participants only used one puff per dose 
analysis was done on number of puffs used. 
Demographics of long term spray users 
No studies were identified that reported this data. 
Predictors related to long term spray use 
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Schneider 2003 + identified that all participants using the nasal spray at 18 months had high 
craving scores (figures not provided) at the beginning of the study, and all but one still mentioned 
craving as a reason for continuing to use the spray. The smoking status of these participants was 
not clear. 
Purchase patterns of long term spray users 
No studies were identified that reported this data.  
4.4. Other NRT products and non-specified NRT 
Study Background 
Hajek 2007 + (prospective cohort) assessed the effect of long-term use of different NRT products 
in smokers attending routine smoking cessation treatment and examined the effect of NRT cost on 
its long term use. Participants were allowed to select their preferred NRT product and advised to 
use it in accordance with the manufacturer's instructions for up to 3 months. Information 
regarding the dose and amount of NRT that was used was not provided. They were seen weekly 
over 6 weeks with the last session scheduled at 4 weeks after their quit date. Patients continued to 
receive NRT as needed via their doctors or pharmacists, collecting prescription forms at the clinic, 
or buying NRT over-the-counter. The clinic treatment was free though the NRT products had 
varying levels of cost. Until April 2001, NRT was sold to participants for up to 1 year at a cost of 
$17 per 1-week supply (during this time participants receiving free prescriptions were entitled to 
one or four weeks free NRT). From April 2001 NRT was provided ‘on prescription’ for up to 1 year, 
contingent on remaining abstinent from smoking. Approximately 70% of clinic patients were 
entitled to receive NRT free of charge, while the rest paid a prescription charge of US $11 for each 
1-week supply (amounts in US$ because paper published in US-based journal). 
Shetty 2010 – (uncontrolled before and after) considered the effect of a trust-wide smoke free 
policy on changes in behaviour, incidents and prescribing in a population of 50 male in-patients at 
a medium secure hospital. Specific details relating to the provision of NRT were not provided. 
Length of time of using NRT product 
Hajek 2007 + reported that only 5% of participants (76/1518) who had quit smoking were still 
using NRT products at 12 months. 
Shetty 2010 – observed that at 12 months post-implementation of a smoke-free policy at a 
medium secure hospital 20% (10/50) of the participants were receiving NRT of whom four had 
received intermittent (not defined) NRT for longer than 12 months (specific details relating to the 
provision of NRT were not provided). 
Pattern of long term NRT use 
Hajek 2007 + reported that at 12 months, only 5% (76/1518) of participants who had quit smoking 
were still were using NRT with 23% (18/76) using spray, 20% (15/76) patches, 13% (10/76) gum, 
24% (18) sublingual tablets, 5% (4) lozenges and 15% (11) an inhalator. 
Demographics of long term NRT users 
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Hajek 2007 + identified that participants who had quit smoking and were long term (12 months) 
NRT users were less likely to have completed education to age 16 compared to those who were 
not using NRT, OR 0.66 (95% CI 0.36, 1.21), p<0.05. 
Predictors related to long term NRT use 
Hajek 2007 + observed that having a higher Fagerström Test of Nicotine Dependence (FTND) score 
(OR 1.20, 95% CI 1.03, 1.40; p=0.02) and smoking for withdrawal relief (OR 1.95, 1.06 to 3.60; 
p=0.03) predicted long term (12 months) NRT use among those who remained cigarette-free. 
FTND mean score for former smokers using NRT at 12 months was 5.6 (SD =2.1) compared to 4.7 
(SD 2.1) for those not using NRT. Previous NRT use, smoking to help concentrate, smoking for 
weight control, educational status and employment were not significant. 
Purchase patterns of long term NRT users 
Hajek 2007 + found that there was no significant difference in long term (12 month) NRT use 
between people entitled to free prescriptions and those who paid for their prescriptions. 
However, there was only a small sample (76) in which to assess the effect of cost. 
4.5. Summary of long term NRT use  
There was considerable variation in the evidence identified in terms of study design, study 
objectives, participant populations and outcomes. Therefore a statistical analysis and synthesis of 
the findings was not appropriate. A narrative summary of the findings is provided together with 
tabulation of mean percentage use of NRT at 12 months among former smokers who had quit 
smoking abruptly. 
NRT use at 12 months among former smokers who had quit smoking abruptly 
The evidence indicates that there are small numbers of individuals who use NRT products over an 
extended period of time. Most of the studies identified looked at 12-month usage of gum or spray. 
Though Schneider 2003 + reported spray use at 18 months and both Blondal 1999 ++ and LHS ++ 
[Murray 1996] reported gum use at five years in small numbers of participants. From the studies 
that provided 12-month follow-up data, 7% (range 3-11%) of individuals who had quit smoking 
were still using NRT, see Table 2. 
Table 2: Mean percent of former smokers using NRT at 12 months who quit smoking 
abruptly 
NRT Use at 12 months among former smokers who quit abruptly 
Study 
NRT 
Product 
Total number 
of 
participants 
provided with 
NRT 
Number of 
participants  at 
12 months who 
had quit 
smoking 
abruptly  
Number of 
participants 
who had quit 
smoking 
abruptly and 
were using NRT 
at 12 months  
% of 
participants 
who had quit 
smoking 
abruptly and 
were using NRT 
at 12 months 
Blondal 1999 ++ 
 
Spray 118 32 4 3 
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Hajek 2007 + 
 
Range of 
products 
1518 Not stated 76  5 
Hatsukami 1993 – Gum 71 63 5 7 
LHS ++ [Bjornson-
Benson 1993; 
Murray 1996; Nides 
1995] 
 
Gum 3923 1069 359 9 
Schneider 2003 +  Spray 92 16 8 9 
Sutherland 1992 ++ Spray 116 30 13 11 
Mean % using NRT 
(range)  
    7 (3-11) 
 Patterns of long term NRT use 
 Dosage: 
 Evidence related to amount of NRT used long term was provided for the use of gum (LHS ++ 
[Bjornson-Benson 1993; Murray 1996], Hughes 2004 –, Johnson 1991 –) and spray (Blondal 1999 
++, Schneider 2003 +). 
LHS ++ [Bjornson-Benson 1993] reported that former smokers who were using nicotine gum at 12 
months were using an average of 8.2 pieces of gum/day (16.4mg/day). 
Hughes 2004 – presented two studies. In study 1 the mean daily dose of nicotine obtained by long 
term users of gum (i.e. use of gum for at least 90 days) was 16mg/day. In Study 2, in which 
participants had self-reported addiction to nicotine gum, the mean daily dose of nicotine obtained 
by gum users was 30mg/day with the median duration of gum use being 32 months (95% CI 15, 50). 
Johnson 1991 – provided data for gum consumption during continuous periods of use (a period of 
continuous use was considered to be time between refills where gum could have been used at a 
consistent average daily dose of eight or more pieces of gum/day, either more than 16 or 
32mg/day assuming that either 2 or 4mg of nicotine /piece) and reported seven periods of 
continuous use of between 12-18 months with consumption of eight or more pieces of gum per 
day. The study also found that six users consumed 50-99 boxes (4,800-9504 pieces) over two years 
and one user may have consumed more than 100 boxes over 2 years. However, it is not clear 
whether this was for personal use or if gum had been shared with another user. 
Blondal 1999 ++ reported that former smokers using a 1mg dose spray at 12 months reported using 
a mean of 22 doses per day (22mg/day). 
Schneider 2003 + indicated that at 18 months one of the five former smokers still using spray was 
using spray above recommended levels (median of 94 sprays/day, approx. 47mg/day). 
The evidence indicates that most long term users of gum and spray are not using them above 
recommended levels; although they may be using products longer than is recommended. The 
British National Formulary (accessed on line: 4 April 2012) recommends that the maximum dose for 
gum is 15 pieces of 4mg/piece per day (60mg/day) and for nasal spray 64 sprays/day (0.5mg/spray) 
equivalent to32mg/day (0.5mg/spray). However it is recommended that users should reduce the 
dose at three months for gum and eight weeks for spray. 
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Product choice: 
Only Hajek 2007 + provided evidence on the type of NRT product chosen by long term users who 
had quit smoking. This study indicated spray to be the product selected most often. 
Reason for use: 
Only Hughes 2004 –, who explored gum use, provided information of the reasons behind 
individuals’ long term (at least 90 days) use of NRT although the sample sizes were small. The study 
found most individuals (72%) used gum to stop smoking or prevent relapse. 
Demographics of long term NRT use 
There was limited information on the demographics of long term NCP users. The LHS ++ [Bjornson-
Benson 1993] identified, of those who had quit smoking, that women were more likely than men to 
use gum long term (12 months). 
Hajek 2007 + reported that of those who had quit smoking and were long term (12 months) NRT 
users were less likely to have completed education to age 16 compared to those who did not use 
NRT long term. 
Hughes 2004 – observed that those were older were more likely to be long term users (at least 90 
days). 
Predictors related to long term NRT use 
Evidence for predictors of long term use was limited. The LHS ++ [Bjornson-Benson 1993] identified 
that being female (p=.002), having a lower BMI (p=0.028), previous history of gum use (p=0.0001) 
or quit attempts (p=0.004) and nicotine dependence variables (seven variables assessed with 
p=0.0001-0.038) were significantly associated with gum use at 12 months. 
Hajek 2007 + also observed that nicotine dependence as defined by the FTND score was associated 
with long term NRT use (OR 1.20, 95% CI 1.03, 1.40; p=0.02) as well as smoking for withdrawal 
relief. FTND mean score for former smokers using NRT at 12 months was 5.6 (SD =2.1) compared to 
4.7 (SD 2.1) for former smokers at 12 months not using NRT. 
Schneider 2003 + reported that all participants using spray at 18 months had higher craving scores 
at baseline. 
Hughes 2004 – observed that those who had smoked for a longer period were more likely to be 
long term users (at least 90 days). 
Purchase patterns of long term NRT users 
There was little evidence regarding purchase patterns of long term users. 
Shiffman 2003 – reported that 0.1% (2/2050) of households purchased patches for 12 months or 
longer and 0.05% (1/2050) for 24 months or longer. In households with persistent patch purchase 
(allowing for a one month gap between purchases) 0.4% (8/2050) purchased for 12 months or 
longer and 0.05% (1/2050) for 24 months or longer. 
Hajek 2007 + found no significant difference in long term (12 months) NRT use between people 
entitled to free prescriptions and those who paid for their prescriptions though there were only a 
small number of long term users (n=76) in which to assess an effect of cost. 
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Evidence Statements:  
4.1 There is moderate evidence of long term (12 months) NRT use in a small number of people 
who had quit smoking. The evidence is provided by three RCTs (Blondal 1999 ++, LHS ++ 
[Bjornson-Benson 1993; Murray 1996; Nides 1995], Sutherland 1992 ++), two prospective 
cohort studies (Hajek 2007 +, Schneider 2003 +) and one UBA (Hatsukami 1993 –). This 
extended use is beyond the length of time that is recommended, treatment is usually 
between eight and 12 weeks before the dose is reduced and eventually stopped. From the 
studies that provided 12-month follow-up data, 7% (range 3-11%) of individuals who had 
quit smoking were still using NRT. This evidence is for nasal spray (Blondal 1999 ++, 
Sutherland 1992 ++, Schneider 2003 +), nicotine gum (LHS ++ [Bjornson-Benson 1993; 
Murray 1996; Nides 1995], Hatsukami 1993 –) and a range of NRT products (Hajek 2007 +). 
4.2 There is moderate evidence that most long term ( ≥ 12 months) use of nicotine gum or spray 
is within recommended dosage limits. The evidence is provided by two RCTs (Blondal 1999 
++, LHS++ [Bjornson-Benson 1993; Murray 1996]), one prospective cohort study (Schneider 
2003 +) and two cross-sectional surveys (Hughes 2004 –, Johnson 1991 –). For this dosage 
evidence participants in Blondal 1999 ++, LHS++ [Bjornson-Benson 1993; Murray 1996] and 
Schneider 2003 + had quit smoking but the smoking status was not reported for 
participants in Hughes 2004 – and Johnson 1991 –. 
4.3  There is moderate evidence from two studies that nicotine dependence at baseline is a 
predictor of long term NRT use at 12 months (LHS ++ [Bjornson-Benson 1993], Hajek 2007 
+). The data was from participants who had all quit smoking. 
This evidence is directly applicable to people in the UK who attempt to quit smoking abruptly. Of 
the studies that reported NRT use at 12 months in former smokers, two studies were conducted 
in the UK (Hajek 2007 +, Sutherland 1992 ++) and three were conducted in community settings 
(Blondal 1999 ++, Hatsukami 1993 –),LHS ++ [Bjornson-Benson 1993; Murray 1996; Nides 1995]. 
 
4.6. Electronic cigarettes (e-cigarettes) 
Study Background 
Etter 2011 + (cross-sectional survey) assessed the profile, utilisation patterns, satisfaction and 
perceived effects among users of e-cigarettes. The data is self-reported and likely to be a highly 
enthusiastic sample of e-cigarette users. The sample included current and former smokers. 
Foulds 2011 – (cross-sectional survey) identified the electronic cigarette products used by 
experienced e-cigarette users, their pattern of e-cigarette use and the impact on tobacco use. The 
participants were a group of highly motivated and enthusiastic e-cigarette users. Of the 104 
respondents 88% (91/104) described themselves as ex-cigarette smokers and 13% (13/104) 
reported making greater than 10% of their income from the e-cigarette business. Comparisons 
were made between users of less than a year (short term users) and users of a year or more (long 
term users). 
Heavner 2010 – (cross-sectional survey) described e-cigarette users’ patterns of cigarette and e-
cigarette usage and smoking cessation attempts and compared health status and smoking 
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attributable symptoms between people who completely switched from smoking to e-cigarettes, 
and those who supplemented cigarette smoking with e-cigarette usage. The data was self-
reported and participants were likely to be highly enthusiastic e-cigarette users. One author is 
Director of E Cigarette Direct, who initiated and conducted the research. 
The two internet surveys involved a self-selected sample and as electronic cigarettes are subject 
to varying levels of country specific regulation and legislation it is likely that the samples are 
biased. For Etter 2011 +  the country distribution of respondents was as follows: 62% USA; 14% 
France; 6% UK; 4% Switzerland; 3% Canada; 11% other countries and for Heavner 2010 – nearly 
75% resided in the USA and 17% in the UK. 
Length of time of using e-cigarettes 
Etter 2011 + reported that 15% (434/2899) of respondents had used e-cigarettes for more than 
one year. Smoking status of these users was not provided. 
Foulds 2011 – found that 54% (56/104) of respondents had been using e-cigarettes for at least 
one year. Smoking status of these users was not provided. 
Heavner 2010 – identified that 3% (9/303) of respondents had been using e-cigarettes for longer 
than 13 months; 2% (5/303) for 13-18 months; 0.3% (1/303) for 19-24 months and 1% (3/303) for 
more than 24 months. Smoking status was not reported. 
Pattern of e-cigarette use 
Foulds 2011 – found that long term users typically used slightly lower nicotine strength liquid than 
short term users. 
Heavner 2010 – reported that seven respondents who had been using e-cigarettes for longer than 
12 months had used them as a complete replacement for cigarettes. Of 142 people who indicated 
that pharmaceutical products (i.e. nicotine gum or patches) did not help them to stop smoking, 
84% (119) used e-cigarettes as a complete replacement for cigarettes. Data was not presented 
separately for those using e-cigarettes for more than 12 months. 
Demographics of long term e-cigarette users 
Foulds 2011 – reported that demographic characteristics did not differ significantly between long 
and short term users. 
Heavner 2010 – observed that on average, respondents who lived in Europe had used e-cigarettes 
for longer than respondents in the US (this may be partly attributed to varying levels and timing of 
country specific regulation and legislation) though were less likely to use e-cigarettes as a 
complete replacement for cigarettes.  
Predictors related to long term e-cigarette use 
No studies were identified that reported this data.  
Purchase patterns of long term e-cigarette users 
No studies were identified that reported this data.  
Evidence Statements:  
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4.4 There is no evidence of e-cigarette use for periods of 12 months or longer in individuals 
who quit smoking abruptly and insufficient evidence of the pattern of use. 
4.5 There is weak evidence from three cross-sectional surveys, possibly of e-cigarette 
enthusiasts, (Etter 2011 +, Foulds 2011 –, Heavner 2010 –) that e-cigarettes are used for 12 
months or longer though only Heavner 2010 – states that some individuals have completely 
replaced cigarettes with e-cigarettes. There was no evidence related to the dosage used by 
long term e-cigarette users. 
4.6 No evidence was identified on predictors or purchase patterns of e-cigarette use. 
The evidence is only partially applicable to people in the UK who quit smoking abruptly. This is 
because e-cigarettes are not licensed for smoking cessation however the evidence does indicate 
that e-cigarettes are used in the UK (Etter 2011 +, Heavner 2010 –) though it does not indicate if 
any of the e-cigarette users quit smoking abruptly. Also the evidence is provided by three cross-
sectional surveys (Etter 2011 +, Etter 2011 +, Foulds 2011 –, Heavner 2010 –Heavner 2010 –) in 
which participants were possibly e-cigarette enthusiasts particularly Foulds 2011 –. 
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5. DISCUSSION 
A variety of settings, interventions and outcomes were studied, which together with a lack of high 
quality studies specifically investigating the long term use of nicotine containing products (NCPs) 
beyond 12 months in former smokers made it difficult to summarise the evidence relating to long term 
use of NCPs. Also some studies reported data related to NRT purchases or prescription refills rather 
than on actual use of NRT. The motivation of participants across the studies varied and in many cases 
was not reported. 
 Of the 15 included studies, ten had a primary focus on the use of NCPs (Etter 2009 +, Etter 2011 +, 
Foulds 2011 −, Hajek 2007 +, Heavner 2010 − , Hughes 2004 −, Johnson 1991 −, Johnson 1992 −, 
Shetty 2010 −, Shiffman 2003 −). Of these studies only Hajek 2007 + had 12 month follow-up data 
specifically concerned with long term NRT use in former smokers and provided details of the NRT 
provision but no information related to dose or amount. Hajek 2007 + was a prospective cohort study, 
Shetty 2010 – was an uncontrolled before and after and the others were cross-sectional surveys (Etter 
2009 +, Etter 2011 +, Foulds 2011 −,Heavner 2010 − , Hughes 2004 −, Johnson 1991 −, Johnson 1992 
−, Shiffman 2003 −).  
Overall there were three studies graded as high quality ++ (Blondal 1999 ++, LHS ++ [Bjornson-Benson 
1993; Murray 1996; Nides 1995], Sutherland 1992). Only three studies were conducted in the UK, 
Hajek 2007 +, Shetty 2010 – and Sutherland 1992 ++. Hajek 2007 + and Sutherland 1992 ++ were 
conducted in a smokers’ clinic and Shetty 2010 – within a medium secure hospital.  
This rapid review provides evidence that some smokers who quit smoking continue to use NRT 
products beyond the recommended period though overall this use is within recommended dosage 
limits. The evidence also suggests that baseline nicotine dependence is a predictor of long term NRT 
use. 
The evidence identified indicates that some users of e-cigarettes do use them for 12 months or longer 
but it is not clear if all users of e-cigarettes use them as a complete replacement for cigarettes. 
 
 
  
Rapid review for NICE: long term use of non-tobacco nicotine containing products in individuals who have quit smoking abruptly 
 
 
32  
 
6.  REFERENCES 
Guyatt G, Oxman AD, Akl E, Kunz R, Vist G, Brozek J, Norris S, Falck-Ytter Y, Glasziou P, Debeer H, 
Jaeschke R, Rind D, Meerpohl J, Dahm P, Schünemann HJ. 2011. GRADE guidelines 1. Introduction-
GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 64(4) 383-
394  
Hughes JR 1998, "Dependence on and abuse of nicotine replacement medications: an update," In 
Nicotine Safety and Toxicity, N. Benowitz, ed., Oxford University Press, pp. 147-157. 
Jones S, Cleves A, Morgan F, Withers K, White J, Dale M. 2011.  ‘Safety, risk and pharmacokinetics 
profiles of tobacco harm reduction technologies. Report v.1.0. Cardiff:  Cedar, October 2011 
Royal College of Physicians of London. 2000. Nicotine addiction in Britain: a report of the Tobacco 
Advisory Group of the Royal College of Physicians .London: Royal College of Physicians, London, pp. 
144.
 
 
Rapid review for NICE: long term use of non-tobacco nicotine containing products in individuals who have quit smoking abruptly 
 
 
33  
 
7. ACKNOWLEDGEMENTS 
We acknowledge with thanks to the following experts and authors in the field who responded to our 
request for evidence and where appropriate suggested additional publications for consideration: 
Professor Paul Aveyard, Primary Care Clinical Sciences, University of Birmingham 
Dr Emma Beard, Department of Epidemiology and Public Health, University College London 
Dr Alex Bobak, Wandsworth Medical Centre, London 
Professor Chris Bolliger, Division of Pulmonology, Stellenbosch University, South Africa 
Professor Ron Borland, Nigel Gray Distinguished Fellow in Cancer Prevention, Cancer Council Victoria, 
Australia 
Professor M J Carpenter, Department of Psychiatry, Hollings Cancer Center, Medical University of 
South Carolina  
Prof Simon Chapman, Sydney School of Public Health, University of Sydney 
Dr J-F Etter, Institute of Social and Preventive Medicine, Faculty of Medicine, University of Geneva 
Dr Karl Fagerström, Smokers Information Centre, Helsberg, Sweden  
Dr Bjorn Fossum, Sophiahemmet University College, Stockholm 
Professor Peter Hajek, Tobacco Dependence Research Unit, Barts and The London School of Medicine 
and Dentistry  
Dr Dorothy Hatsukami, Associate Director of Cancer Prevention and Control, Masonic Cancer Center, 
University of Minnesota 
Professor John Hughes, Professor of Psychology, University of Vermont 
Dr Richard Hurt, Director, Mayo Clinic Nicotine Dependence Center, Minnesota 
Dr Carlos Jimenez-Ruiz, Public Health Institute, Madrid 
Dr Andy McEwan, Senior Research Associate and Assistant Director of Tobacco Studies, University 
College London 
Dr Charlotta Pisinger, Research Centre for Prevention and Health, Capital Region of Denmark 
Professor Stephen Rennard, Pulmonary and Critical Care, University of Nebraska Medical Center 
Professor Riccardo Polosa, Centre for Tobacco Research, University of Catania, Italy 
Dr Catherine Sykes, Department of Psychology, City University, London 
Dr Thordis Thomsen, Department of Anaesthesiology, Herlev University Hospital  
Professor Melanie Wakefield, Director of the Centre for Behavioural Research in Cancer, Cancer 
Council Victoria, Australia 
Dr Mike Ward, Consultant Physician, Sherwood Forest Hospitals 
Professor David Warner, Anesthesia Clinical Research Unit, Mayo Clinic, Minnesota 
Professor Robert West, Department of Epidemiology and Public Health, University College London 
Rapid review for NICE: long term use of non-tobacco nicotine containing products in individuals who have quit smoking abruptly 
 
34  
 
APPENDIX A – INCLUDED STUDIES - EVIDENCE TABLES  
First author and year:   
Blondal 1999 
Aim of study: 
To evaluate the 
efficacy of using a 
nicotine patch for 5 
months with a nicotine 
nasal spray for 1 year. 
Study Design : 
RCT 
Quality score: 
++ 
External validity score: 
+ 
 
Setting: 
Community; Reykjavik, Iceland 
Participants: 
Smokers aged 22-66 years; 67% 
female; 17% with history of 
treatment for alcoholism 
Inclusion: 
Aged 21-69 years; Smokers of 
at least one cpd for ≥ 3 years. 
Exclusion: 
History of recent myocardial 
infarction; severe nasal allergy; 
skin disease; smokeless tobacco 
users; alcohol misusers; 
pregnant or breast feeding. 
Motivation of participants: 
Probably motivated to quit 
since responders to adverts in 
local papers and on television. 
 
Method of allocation: 
Computer generated 
randomisation 
Intervention(s): 
Nicotine patch for 5 months 
(tapering from 15 mg for 3 
months, 10 mg at month 4 to 
5 mg at month 5) with 
nicotine nasal spray 
(0.5mg/dose/nostril) for 1 
year 
Control: 
Nicotine patch for 5 months 
(as above) with placebo nasal 
spray for 1 year. 
Both groups received 
support. 
Sample sizes: 
237 with I: 118, C: 119 
Baseline comparisons: 
Similar 
Study power: 
Numbers estimated for 90% 
power and a 5% significance 
level. 
Intervention delivery: 
Smoking clinic staff.   
 
Primary outcomes: 
Sustained smoking abstinence 
(CO verified as <10 ppm). Blood 
cotinine also measured.  
Secondary outcomes: 
None 
Follow-up periods: 
6 weeks; 3,6 and 12 months; 6 
years 
Method of analysis: 
Chi squared statistic for 
proportions of abstainers at each 
time point.  Kaplan-Meier 
method for measuring abstinence 
over time.  Parametric t-tests for 
continuous variables with normal 
distributions and Mann-Whitney 
rank tests for non-normal 
distributions. 
Length of time of using NCP and/or 
prevalence of use:  
At 12 months 32 participants in the 
intervention group were abstainers 
of which 13% were using nasal spray 
with mean of 22 (SD 9) self-reported 
1mg doses per day.  In the placebo 
group there were 13 abstainers, none 
of whom were using the placebo 
nasal spray. 
At 12 months 4 abstainers in the 
intervention group who were still 
using the nicotine nasal spray after 
12 months had higher cotinine levels 
than baseline (mean 131% compared 
to baseline). Of these one relapsed 
during the 2nd year, two during 3rd 
year and the 4th
At 5 years 2 of 22 participants in the 
intervention group (9.1%) were using 
nicotine chewing gum occasionally. 
 remained abstinent 
throughout the study. 
Pattern of NCP use: 
None 
Demographics of long term NCP 
users: 
None 
Predictors related to long term NCP 
use: 
None 
Purchase patterns: 
None 
Attrition: 
99% completed follow ups 
 
Limitations (author):  
None  
Limitations (review team): 
High quality study other 
than self-reported 
outcomes only for NRT use 
(though would be difficult 
to confirm).  Two authors 
were employed by, and one 
consulted for, Pharmacia 
and Upjohn. Pharmacia and 
Upjohn measured the 
cotinine concentrations but 
the trial is described as 
double blind. 
Evidence gaps: 
None 
Funding sources: 
Pharmacia and Upjohn 
Applicable to UK? 
The support provided may 
be different in Iceland 
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First author and year:   
Etter 2009 
Aim of study: 
To assess use of, and 
dependence, on 
nicotine gum in former 
smokers. 
Study Design : 
Cross-sectional survey 
Quality score: 
+ 
External validity score: 
+ 
Setting: 
Community. Internet survey 
'survey for users of nicotine 
chewing gums'. 
Participants: 
526 daily users of nicotine gum. 
For users of gum > 3 months 
36.8% men, median age 47 
years, median income 82.8% of 
national average; median days 
since quitting smoking 960. 
Inclusion: 
Nicotine gum users; 
assumption of smoking 
abstinence 
Exclusion: 
None 
Motivation of participants: 
Self-selected visitors to tobacco 
cessation web site. 
 
Sample sizes: 
526 
How were the data 
collected: 
• What method(s): 
Self-initiated completion of 
internet survey in English on 
the StopTabac.ch web site 
with a link from other 
smoking cessation web sites. 
After 30 days, participants 
who agreed and indicated an 
email address received a 
message asking whether they 
were still using NRT and their 
level of craving for NRT gum. 
• By whom: 
University researchers s 
• What setting(s): 
Community. Internet survey 
of users of nicotine gum 
• When: 
Nov 2004-Oct 2007 
 
Primary outcomes: 
Numerous characteristics of 
participants, their NRT gum use, 
nicotine dependence, cigarette 
dependence and cigarette 
craving. 
Method of analysis: 
T tests to compare means, Mann-
Whitney U tests to compare 
medians, chi square tests to 
compare proportions and linear 
regression models to test 
associations between continuous 
variables. 
Length of time of using NCP and/or 
prevalence of use: 
Of respondents 302 had used gum 
for > 3 months. 
Median days use for smokers using 
NRT for > 3 months = 730 days. 
60.1% of users for >3 months 
answered that stopping all NRTS 
would be 'difficult' or 'impossible'. 
49.5% of these users rated their 
addiction to gum as similar to, or 
stronger than their former addiction 
to cigarettes. 
Pattern of NCP use: 
None 
Demographics of long term NCP 
users: 
None 
Predictors related to long term NCP 
use: 
None 
Purchase patterns: 
None 
 
Limitations (author):  
Survey likely to attract 
users with concerns about 
long term gum use. 
Limitations (review team): 
Self-selected sample. 
Unlikely to be 
representative of all gum 
users. Self-reported data.  
Mean duration of gum use 
was more than 2 years but 
authors described long 
term use as > 3 months.  No 
separate data for 12 
months plus.  Authors 
received financial support 
from Pfizer and Novartis, 
gum producers. 
Evidence gaps: 
Studies to examine 
prevalence of dependence 
among NRT users 
Funding sources: 
None.  
University of Geneva 
received financial support 
from Pfizer and Novartis, 
producers of NRT products, 
to develop online smoking 
cessation programs for NRT 
users under the supervision 
of JFE 
Applicable to UK? 
Quite likely relevant to 
internet site users with 
concerns about NRT 
addiction. 
 
Rapid review for NICE: long term use of non-tobacco nicotine containing products in individuals who have quit smoking abruptly 
 
 
36  
 
First author and year:   
Etter 2011 
Aim of study: 
To assess the profile, 
utilization patterns, 
satisfaction and 
perceived effects 
among users of 
electronic cigarettes. 
Study Design : 
Cross-sectional survey 
Quality score: 
+ 
External validity score: 
−  
Setting: 
Community. Internet survey. 
Country distribution of 
respondents: 62% USA; 14% 
France; 6% UK; 4% Switzerland; 
3% Canada; 11% other 
countries.  
Participants: 
3,587; 70% former smokers; 
61% men; mean age 41 years; 
household income 27.% below 
average, 30.9% average, 36.4% 
above average;  median 
duration of e-cigarette use 3 
months.   
Inclusion: 
>18 years; current, past or 
never user of e-cigs 
Exclusion: 
None 
Motivation of participants: 
Not provided 
Sample sizes: 
3,587 
How were the data 
collected: 
• What method(s): 
Self-initiated completion of 
internet survey in English & 
French on web sites and 
online discussion forums 
dedicated to e-cigarettes & 
smoking cessation. 
• By whom: 
University researchers 
• What setting(s): 
Community. Internet survey 
of users of e-cigarettes 
• When: 
March-Oct 2010 
Primary outcomes: 
Participant characteristics, 
utilization and satisfaction with e-
cig use; reasons for use, for 
stopping use and withdrawal 
symptoms; comparisons 
(current/former smokers, forum 
vs web site respondents). 
Method of analysis: 
Analysis of variance (ANOVA) to 
compare means; Mann-Whitney 
U tests for medians, chi square 
tests for proportions. Linear 
regressions (95% CI) to test 
associations between continuous 
variables. 
Length of time of using NCP and/or 
prevalence of use: 
15% (434/2899) of the sample had 
used e-cigs for more than 1 year.   
Pattern of NCP use: 
None 
Demographics of long term NCP 
users: 
None 
Predictors related to long term NCP 
use: 
None 
Purchase patterns: 
None 
 
Limitations (author):  
Predominantly self-selected 
users of web sites 
dedicated to e-cigs. 
Limitations (review team): 
Self-reported data.  Likely 
to be highly enthusiastic 
sample. 
Evidence gaps: 
Need to address the safety 
and efficacy of the 
products. 
Funding sources: 
Not stated. 
Applicable to UK? 
Quite possibly (for e-cig 
enthusiasts) 
First author and year:   
Foulds 2011 
Aim of study: 
To identify the e-cig 
products used by 
experienced e-cig 
users, their pattern of 
e-cig use and the 
impact on tobacco use 
Study Design : 
Cross-sectional survey 
Quality score: 
- 
External validity score: 
− 
Setting: 
Meeting of e-cigarette 
enthusiasts; Philadelphia, USA 
Participants: 
E-cigarette users attending a 
meeting of electronic cigarette 
enthusiasts; 74% male; 88% 
white; 40% with college 
degree;  mean age 34; 77% 
employed full-time 
Inclusion: 
E-cigarette users 
Exclusion: 
Not provided 
Motivation of participants: 
Sample sizes: 
104 responses from e-
cigarette users from 110 
questionnaires (94.5%), 48 
short term users (<12 
months) and 56 long term (1 
year or more) 
• What method(s): 
Questionnaire handed out at 
a meeting of e-cigarette 
enthusiasts. 
• By whom: 
University researchers 
• What setting(s): 
Meeting (Philly Vapefest 
Primary outcomes: 
E-cig use history, tobacco use 
history, beliefs about e-cigs 
Method of analysis: 
Descriptive statistics plus 
statistical comparisons (chi-
squared, independent t-test, 
Mann-Whitney U test) between 
long and short term users 
Length of time of using NCP and/or 
prevalence of use: 
56 (54%) respondents had been using 
e-cigs for at least a year. 
Pattern of NCP use: 
None 
Demographics of long term NCP 
users: 
Demographic characteristics did not 
differ significantly between long and 
short term users. Long term users did 
typically use slightly lower nicotine 
strength liquid than short term users. 
Predictors related to long term NCP 
use: 
Limitations (author):  
None reported 
Limitations (review team): 
Group of highly motivated 
and enthusiastic e-cigarette 
users and may not be 
generalisable outside this 
group. 13% of respondents 
making > 10% of their 
income from e-cigarette 
business.   
Evidence gaps: 
Urgent need to establish a 
safety profile for e-
cigarettes and, if 
acceptable, to assess 
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Motivated e-cigarette users 
 
2011) 
• When: 
2011 
  
None 
Purchase patterns: 
None 
 
efficacy in appropriately 
designed clinical trials 
Funding sources: 
No information provided. 
Lead author has worked as 
paid consultant for 
manufacturers of smoking 
cessation aids. 
Applicable to UK? 
Yes but only to a sample of 
people with the same 
characteristics of those in 
this study. 
First author and year:   
Hajek 2007 
Aim of study: 
To assess the effect of 
long-term use of 
different nicotine 
replacement treatment 
products in smokers 
attending routine 
smoking cessation 
treatment and to 
examine the effect of 
nicotine replacement 
treatment cost on its 
long-term use. 
Study Design : 
Prospective cohort 
Quality score: 
+ 
External validity score: 
++ 
Setting: 
Smoker's clinic in East London, 
between January 2000 & 
November 2002 
Participants: 
Consecutive participants using 
NRT treatment who set a quit 
date.  Mean age 48 (SD 14); 
mean CPD 23 (SD 10); 56% 
female, 31% in paid 
employment; 60% completed 
education to 16 years. 
Inclusion: 
Participants using NRT who had 
set a quit date at the clinic.   
Exclusion: 
None 
Motivation of participants: 
Smoking cessation clinic 
attendees. 
Method of allocation: 
Not applicable 
Intervention(s): 
NRT prescription for 
attendees to a smokers' clinic 
and follow up at 12 months. 
3-month programme of 
treatment at the clinic 
combines medication (with 
advice to use for up to 3 
months) and behavioural 
support (the UK Stop 
Smoking Service).  Until April 
2001 NRT was sold to 
participants for up to one 
year at a cost of $17 per 
week.  From April 2001 
prescription was free for up 
to one year contingent on 
continuing abstinence (with 
free prescription for circa 
70% of participants and $11 
per week for others). 
Control: 
Not applicable 
Sample sizes: 
Primary outcomes: 
Demographic and smoking 
characteristics, test of nicotine 
dependence, motives for 
smoking and expired CO. 
Duration of NRT use at 12 month 
follow up. 
Secondary outcomes: 
None 
Follow-up periods: 
12 months 
Method of analysis: 
Analysis of variance to explore 
correlation of demographic 
variables with smoking 
characteristics (1-year abstainers 
still using NRT, 1-year abstainers 
not using NRT and 1-year 
smokers). Chi squared, univariate 
ANOVA and logistic regression to 
assess predictors of long-term 
NRT use. 
Length of time of using NCP and/or 
prevalence of use: 
76 of 1,518 participants (5%) were 
using NRT at 12 months after their 
quit date.  All had been continuously 
abstinent. 
Pattern of NCP use: 
Of all long term users(n=76) 20% 
used the transdermal patch, 24% 
sublingual tablet, 5% lozenge, 15% 
inhalator, 13% chewing gum and 24% 
nasal spray. 
Demographics of long term NCP 
users: 
Long term abstinent NRT users were 
less likely to complete education to 
age 16 compared to NRT free status 
abstainers OR 0.66 (95% CI 0.36, 
1.21), p<0.05. 
Predictors related to long term NCP 
use: 
Two factors predicted long term NRT 
use among continuous abstainers:  
higher Fagerström Test of Nicotine 
Dependence (OR 1.20, 95% CI 1.03, 
1.40) p=0.02 and smoking for 
Limitations (author):  
No data on the 
consumption of NRT or self-
reported reasons for long 
term use. Small sample (76) 
in which to assess an effect 
of cost. 
Limitations (review team): 
Self-report only. 
Evidence gaps: 
Examine consumption 
patterns and reasons for 
long term use. Re-
examination of licencing 
restrictions. 
Funding sources: 
Not stated 
Applicable to UK? 
Yes, London based study. 
Authors noted that the 
sample were typical of 
smokers seeking treatment 
in the UK 
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1,518 
Baseline comparisons: 
Not applicable 
Study power: 
Not reported 
Intervention delivery: 
Smokers clinic personnel 
 
withdrawal relief (OR 1.95, 1.06 to 
3.60) p=0.03. Previous NRT use, 
smoking to help concentrate, 
smoking for weight control, 
educational status and employment 
were not significant. 
Purchase patterns: 
There was no significant difference in 
long-term NRT use between people 
entitled to free prescriptions and 
those who paid for their 
prescriptions. 
Attrition: 
ITT used. 
First author and year:   
Hatsukami 1993 
Aim of study: 
To examine if longer 
duration on nicotine 
gum promoted 
dependence on 
nicotine gum 
Study Design : 
Uncontrolled before 
and after 
Quality score: 
− 
External validity score: 
+ 
 
Setting: 
Recruited from community 
(USA) and conducted in 
research laboratory 
Participants: 
71; 51% male; mean age 38.3 
(SD 9.3)  
Inclusion: 
Smoke at least 1 pack/day; no 
use of other tobacco products; 
no previous use of nicotine 
gum; motivation to quit 
smoking; fulfil DSM-III-R criteria 
for a history of nicotine 
withdrawal; not undergoing 
treatment for any psychiatric 
disorder; not abusing alcohol or 
drugs; no current use of 
psychoactive medications; no 
medical contraindications to 
nicotine gum use. 
Exclusion:  
Present or planned pregnancy 
Motivation of participants: 
Method of allocation: 
Not provided 
Intervention(s): 
Use of 2mg gum for 1 or 3 
months, attendance at 
weekly individual sessions. 
Each participant provided a 
$50 deposit to be returned if 
they were abstinent from 
smoking at the end of 
treatment. Participants in the 
1-month group who complied 
with study procedures (were 
paid $50; those in the 3-
month group were paid $150. 
Control: 
No control group. 
Sample sizes: 
1 month group: 33; 3 month 
group: 38 
Baseline comparisons: 
No significant difference 
between groups or between 
those who did or did not 
Primary outcomes: 
Weekly smoking status with 
biochemical verification and 
withdrawal symptoms, gum use 
Follow-up periods: 
1, 6 and 12 month 
Method of analysis: 
Chi-square, t-tests and analysis of 
variance 
Length of time of using NCP and/or 
prevalence of use: 
At 12 months 5/63 participants 
reported regular gum use since last 
follow-up at 6 months post-
cessation. 
Pattern of NCP use: 
At the 12 month 15 participants had 
discontinued gum were smoking 
again, 4 participants had 
discontinued gum and were 
abstinent and 1 participant was still 
using gum and was abstinent from 
smoking. 
Demographics of long term NCP 
users: 
No details 
Predictors related to long term NCP 
use: 
No details 
Purchase patterns: 
No details 
Attrition: 
63/71 (88.7%) contacted at all three 
Limitations (author):  
Small sample and no 
biochemical verification at 
follow-up. Lack of placebo. 
The 3 month group had 
more frequent contact than 
the 1 month group. Lack of 
information on whether 
groups were comparable in 
degree of cigarette 
withdrawal symptoms. 
Limitations (review team): 
Lack of detail on source 
population 
Evidence gaps: 
 None stated. 
Funding sources: 
National Institute on Drug 
Abuse. Marion Merrell Dow 
research Institute provided 
the nicotine gum. 
Applicable to UK? 
Yes 
Rapid review for NICE: long term use of non-tobacco nicotine containing products in individuals who have quit smoking abruptly 
 
 
39  
 
Motivated to quit 
 
complete treatment. 
Study power: 
No details 
Intervention delivery: 
Researchers 
follow-up periods. 
 
First author and year:   
Heavner 2010 
Aim of study: 
To describe e-cigarette 
users' patterns of 
cigarette and e-
cigarette usage and 
smoking cessation 
attempts and to 
compare health status 
and smoking-
attributable symptoms 
between people who 
completely switched 
from smoking to e-
cigarettes, and those 
who supplemented 
cigarette smoking with 
e-cigarette usage. 
Study Design : 
Cross-sectional survey 
Quality score: 
− 
External validity score: 
− 
Setting: 
Community. Internet survey in 
English with links from the E 
Cigarette Direct website, 
various blogs and online 
forums. Nearly 75% resided in 
the USA and 17% in the UK. 
Participants: 
Convenience sample enrolled 
from E Cigarette Direct 
consumers, website visitors 
and users of an e-cigarette 
forum. 72% from the USA, 21% 
from Europe.  55% aged 31-50 
and 32% > 50 years old. 
Inclusion: 
None 
Exclusion: 
None 
Motivation of participants: 
Mixed, but a majority who tried 
to quit smoking and failed, but 
then succeeded by switching to 
e-cigarettes. 
 
Sample sizes: 
303 (270 excluding possible 
duplicates) 
How were the data 
collected: 
• What method(s): 
Completion of internet 
survey  
• By whom: 
Director of E Cigarette Direct, 
who initiated and conducted 
the research and analysis 
carried out by independent 
university researchers  
• What setting(s): 
Community. Internet survey. 
• When: 
May-June 2009 
 
Primary outcomes: 
Patterns of use and health status. 
Method of analysis: 
Frequencies of all variables – 
univariate and bivariates analyses 
- (no confidence limits reported) 
and summary of freehand 
comments. 
Length of time of using NCP and/or 
prevalence of use: 
Only 9/303 respondents (3% of the 
sample) had been using e-cigarettes 
for 13+ months, 2% (5/303)  for 13-
18 months, 0.3% (1/303)  for 19-24 
months and 1%(3/303)  > 24 months. 
Pattern of NCP use: 
Of respondents 7 had been using e-
cigarettes for >12 months as a 
complete replacement for cigarettes. 
119 (84%) respondents who 
indicated that pharmaceutical aids 
did not help them to stop smoking 
used e-cigarettes as a complete 
replacement for cigarettes. Data not 
presented separately for those using 
e-cigarettes >12 months. 
Demographics of long term NCP 
users: 
On average, respondents who lived 
in Europe had used e-cigarettes for 
longer than respondents in the US, 
but were less likely to use e-
cigarettes as a complete replacement 
for cigarettes.  
Predictors related to long term NCP 
use: 
None 
Purchase patterns: 
None 
Limitations (author):  
Highly motivated and 
passionate e-cigarette 
users.  Noted that some of 
the questions were 
imprecise and some 
answers difficult to 
interpret (e.g. users who 
reported better health 
might describing the 
benefits of reduced 
smoking overall or ease of 
smoking withdrawal 
symptoms in smoke-free 
situations). 
Limitations (review team): 
Self-report only. Likely to 
be a highly biased sample 
so difficult to make any 
conclusions about general 
patterns of e-cigarette use. 
One author is Director of E 
Cigarette Direct, who 
initiated and conducted the 
research. 
Evidence gaps: 
Future surveys should ask 
respondents to indicate the 
number of cigarettes that 
they smoked (per day) 
before using e-cigarettes 
and the number that they 
smoked after starting to 
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 use e-cigarettes, as well as 
when and where they 
smoke and use e-cigarettes. 
Funding sources: 
Not stated 
Applicable to UK? 
Possibly to highly 
motivated users but no 
licensed products in the UK 
as yet. 
First author and year:   
Hughes 2004 
Aim of study: 
To estimate the misuse 
of and dependence on 
over-the-counter 
nicotine gum in a 
volunteer sample 
Study Design : 
Two cross-sectional 
telephone surveys 
Quality score: 
- 
External validity score: 
++ 
 
Setting: 
Community. North-eastern 
states in the USA 
Participants: 
Study 1: 266 participants; 62% 
women; mean age 46; mean 
CPD when last smoked 21 
Study 2: 100 participants; 59% 
women; mean age 50; mean 
CPD when last smoked 30 
Inclusion: 
Study 1: Age 18 years or older, 
smoked daily in the past, used 
at least one piece of nicotine 
gum on at least two of the last 
four days 
Study 2: Believed they were 
addicted to nicotine gum, 
currently used nicotine gum at 
least once per week, used gum 
for at least one month and 
used at least two pieces of gum 
in the past four days, age 18 
years or older, smoked in the 
past. 
Exclusion: 
None 
Motivation of participants: 
Sample sizes: 
Study 1: 266 participants 
Study 2: 100 participants 
How were the data 
collected: 
• What method(s): 
Telephone interview 
• By whom: 
Not stated 
• What setting(s): 
Community 
• When: 
Study 1: 1997 
Study 2: 2000 
 
 
Primary outcomes: 
Study 1: Gum use, reasons for 
nicotine gum use, concurrent 
gum and cigarette use. Long term 
use was considered to be ≥90 
days. 
Study 2: Gum use, dependence 
Method of analysis: 
Descriptive statistics.  Logistic 
regression in study 1 to 
determine whether selected 
variables predicted initial 
purchase of the gum to reduce 
vs. stop smoking, long vs. short 
term use of the gum, and 
addiction as a reason for 
continuing use of the gum. 
Length of time of using NCP and/or 
prevalence of use: 
Study 1: 46% of the sample had used 
the gum for longer than the 
recommended three months.  Among 
the long term users, the median 
number of days of use was 242 (25th-
75th
Study 2: the median duration of gum 
use was 32 months (95% CI=15-50). A 
total of 98% (CI=96%-100%) of 
participants had used gum for at 
least 3 months. The mean daily dose 
of nicotine at the time of the 
interview was 30mg/day (SD=20). 
 percentile 158-409), and the 
mean number of milligrams of 
nicotine per day from gum was 16 
(SD=11). 
Pattern of NCP use: 
Study 1: at the time of the survey 
most long-term users were using 
gum to stop smoking or prevent 
relapse (72%) and only 8% for non-
cessation reason. 20% spontaneously 
volunteered addiction as the reason 
for their continued use. 
Study 2: at the time of the survey 
12% were concurrent gum and 
cigarette users. A total of 92% (CI 
Limitations (author):  
Volunteer samples so 
results may not be 
applicable to national 
samples. Single cross-
sectional surveys which 
tend to oversample those 
with chronic conditions.  
Possible bias in the 
recruitment strategy 
towards those who were 
addicted to NRT. Volunteer 
samples often have a 
higher prevalence of and 
more severe forms of a 
disorder than population 
based samples. 
Limitations (review team): 
Small samples and self-
report 
Evidence gaps: 
Explore post-relapse 
concurrent use of NRT and 
cigarettes. 
Funding sources: 
Grants from Pharmacia 
(Pfizer), SmithKline 
Beecham, the National 
Institute on Drug Abuse, 
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Mixed 
 
87%,97%) purchased gum initially to 
stop smoking or prevent relapse, 2% 
(CI0%, 5%) to reduce smoking and 4% 
(CI 0%, 8%) to avoid restrictions. 65% 
(CI 55%, 74%) reported inability to 
control use, 75% (CI 66%, 84%) 
reported difficulty stopping, 61% (CI 
46%, 76%) reported that stopping 
gum was extremely difficult, 
compared to 59%  (44%, 74%) who 
reported that stopping cigarettes was 
extremely difficult.  
Demographics of long term NCP 
users: 
Study 1: Those who were older were 
more likely to be long term users 
(p<.0001). 
Predictors related to long term NCP 
use: 
Study 1: Those who had smoked 
longer were more likely to be long 
term users (p<.0001). 
Purchase patterns: 
None 
and Institutional Training 
Grant. 
The first author had several 
competing interests. 
Applicable to UK? 
Yes 
First author and year:   
Johnson 1991 
Aim of study: 
To describe the extent 
of nicotine chewing 
gum use among health 
maintenance 
organization members, 
the characteristics of 
prescribers and users, 
and the patterns of 
gum use over a two-
year period. 
Study Design : 
Setting: 
Health Maintenance 
Organization, Kaiser 
Permanente (KP), USA and  
Canada 
Participants: 
1970 KP members between 1 
July 1987 and 30 June 1989 
(4505 prescriptions for nicotine 
gum). 56.3% female; 86.1% 
aged 25-64. 
Inclusion: 
KP members  
Exclusion: 
Method of allocation: 
Not applicable 
Intervention(s): 
Nicotine gum prescription 
Control: 
Not applicable 
Sample sizes: 
1970 KP members who 
received 4505 prescriptions 
for nicotine gum dispensed 
from outpatient pharmacies 
Baseline comparisons: 
Not applicable 
Primary outcomes: 
Extent of nicotine gum use, users, 
use and charges by prepaid drug 
benefit, prescribers, patterns of 
use, average daily dosage and 
duration of use.  
Follow-up periods: 
Not applicable 
Method of analysis: 
Chi-square tests with Yates’ 
correction for categorical data 
and t-tests for continuous data. 
Length of time of using NCP and/or 
prevalence of use: 
11% (216/1970) of users with four or 
more prescriptions, 90% (195/216) 
had periods of continuous use which 
resulted in a total of 218 periods.  
30%of continuous use periods >6 
months, with longest period being 19 
months. [Period of continuous use = 
time between refills where gum 
could have been used at a consistent 
average daily dose (≥8 pieces of 
gum)] 
Pattern of NCP use: 
6/1970 users consumed 50-99 boxes 
Limitations (author):  
None 
Limitations (review team): 
No data provided on actual 
number of users and length 
of continuous use or how 
many users and gum dose. 
No data collected on 
smoking behaviour. 
Evidence gaps: 
Use of gum in relation to 
past smoking history and 
current smoking status of 
users. Also in relation to 
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Cross-sectional survey 
Quality score: 
− 
External validity score: 
+ 
 
None stated 
Motivation of participants: 
Not provided 
 
Study power: 
Not applicable 
Intervention delivery: 
Not applicable 
 
(box = 96 pieces) over two years. 
2/1970 consumed ≥100 boxes, not 
stated if for personal use or if shared. 
Continuous use of 12-18 months: 10 
periods involved <8 pieces/day and 7 
periods involved ≥8 pieces/day. 
≥ 18 months 2 periods involved <8 
pieces/day and 4 periods involved ≥8 
pieces/day. 
Demographics of long term NCP 
users: 
None 
Predictors related to long term NCP 
use: 
None 
Purchase patterns: 
None 
their knowledge and 
attitudes about nicotine 
gum and potential adverse 
effects. Funding sources: 
Not provided 
Applicable to UK? 
Yes 
First author and year:   
Johnson 1992 
Aim of study: 
To assess nicotine gum 
use when prescribed in 
a non-research, routine 
outpatient setting. 
Study Design : 
Cross-sectional survey 
Quality score: 
− 
External validity score: 
+ 
Setting: 
Health Maintenance 
Organization, Kaiser 
Permanente (KP), USA & 
Canada 
Participants: 
KP members who were 
recipients of nicotine gum 
prescriptions from outpatient 
pharmacies between 1 July 
1987 and 1 Jan 1989. Regular 
smokers of cigarettes during 
last 3 years. Median age 45 
years (range 15-78); 54.6% 
female. 
Inclusion: 
Recipient of prescription for 
nicotine gum. 
Exclusion: 
No address within KP 
Sample sizes: 
612/1224 gum users 
selected. 529 contacted and 
498 completed 
questionnaires. 
How were the data 
collected: 
• What method(s): 
Questionnaires. Where these 
were not returned, recipients 
contacted by phone and 
questionnaire completed as a 
phone interview. 
• By whom: 
Not stated 
• What setting(s): 
Community. 
• When: 
Jan-April 1990. 
Primary outcomes: 
Smoking history and nicotine 
gum use. 
Method of analysis: 
Descriptive only – numbers and 
percentages of respondents. 
Length of time of using NCP and/or 
prevalence of use: 
Of 428 participants 4.4% reported 
using nicotine gum between 1-2 
years and 2.8% reported use for >2 
years. 
Pattern of NCP use: 
None 
Demographics of long term NCP 
users: 
None 
Predictors related to long term NCP 
use: 
None 
Purchase patterns: 
None 
 
Limitations (author):  
None 
Limitations (review team): 
None 
Evidence gaps: 
None stated 
Funding sources: 
Not provided 
Applicable to UK? 
Yes 
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membership file; KP 
employees; participants in 
ongoing smoking cessation 
studies 
Motivation of participants: 
Not provided 
First author and year:   
Lung Health Study 
(LHS): 
Bjornson-Benson 1993; 
Murray 1996; Nides 
1995 
[Background 
information from Buist 
1993; Connett 1993; 
O’Hara 1993;] 
Aim of study: 
To evaluate the 
efficacy of early 
intervention for 
chronic obstructive 
pulmonary disease 
among cigarette 
smokers who have mild 
to moderate 
impairment in 
pulmonary function. 
Study Design : 
RCT 
Quality score: 
++ 
External validity score: 
++ 
 
Setting: 
USA and Canada – community-
based 
Participants: 
5887 recruited from local 
worksites and shopping malls; 
63% male; average age 48 yrs 
(97% white; 63% males. 
Inclusion: 
Cigarette smokers, aged 35-60; 
mild to moderate airflow 
obstruction 
Exclusion: 
Health conditions likely to 
affect lung function; unable to 
participate in a 5-year follow-
up. 
Motivation of participants: 
Willingness to consider 
smoking cessation 
 
Method of allocation: 
Computer generated 
randomisation schedule 
Intervention(s): 
Special intervention with 
either bronchodilator (SI-A) 
or placebo (SI-P) inhaler plus 
a multisession behavioural 
program., Additionally, 
smoking cessation 
maintenance activities, 4-
monthly scheduled clinic 
visits plus 2mg/piece nicotine 
gum after quitting. 
Control: 
Usual care (UC) 
Sample sizes: 
73,694 screened 
5887 eligible: SI=3923, 
UC=1962. 
Baseline comparisons: 
Only minor difference 
between SI and UC groups. 
Significant differences 
between men and women on 
most variables. 
Study power: 
The power for detecting a 
7.5ml/year effect of the 
combined smoking 
intervention and 
bronchodilator programs (UC 
Primary outcomes: 
Rate of decline (in ml/year) of 
FEV₁ 
Secondary outcomes: 
Mean absolute decline in FEV₁ 
from baseline to 5th
Follow-up periods: 
 annual visit; 
rates of decline and absolute 
decline in other pulmonary 
function parameters; mortality; 
morbidity 
4 monthly up to 5 years. 
Method of analysis: 
Self-report together and/or with 
statistical analysis 
Length of time of using NCP and/or 
prevalence of use: 
At 5 years 14% of ex-smokers were 
using nicotine gum and 5% of 
participants unsuccessful at quitting 
smoking were using gum. Total 
number of ex-smokers and smokers 
not provided (Murray 1996). 
At 12 months 33.6% of 1069 
sustained non-smokers, 19.2% of 
2071 continuing smokers and 54.5% 
of 595 intermittent smokers were 
using nicotine gum. Intermittent non-
smokers, those that had a non-
smoking status at the time of the 
follow-up visit but overall reported a 
smoking pattern that included at 
least 1 month each of smoking and 
non-smoking in the 8 months prior to 
the 12 month visit, were more likely 
to be using gum than any other 
group, p<0.001 (Bjornson-Benson 
1993). 
Pattern of NCP use: 
At 12 months sustained non-smokers 
were using nicotine gum at an 
average of 8.2 pieces/day. Average 
pieces of gum/day were significantly 
different for intermittent smokers 
and intermittent non-smokers, 7.5 
and 9.7 respectively, p<0.001 
(Bjornson=Benson 1993) 
Among ex-smokers from the 
Limitations (author): SI 
participants provided with 
free nicotine gum; likely 
that they used more as a 
consequence and would 
have been encouraged to 
use the gum. 
Limitations (review team): 
Self-report of gum use. 
Large study with a specific 
primary outcome of 
interest. Long term use of 
NRT was not a primary 
focus so difficult to extract 
specific data. 
Evidence gaps: 
Long term users should be 
closely monitored. Smoking 
cessation programmes 
should emphasize 
techniques for coping with 
discontinuing the use of 
nicotine replacement. 
Funding sources: 
National Heart, Lung and 
Blood Institute, NIH 
Applicable to UK? 
Yes 
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vs SI-A) is approximately 0.94 
Intervention delivery: 
Range of health professional 
& researchers 
 
intervention groups the level of gum 
use trended upwards over the course 
of the study (4-60 months) from 8 to 
10 pieces/day. The level of use by 
smokers ranged between 6 and 7 
pieces/day (Murray 1996) 
Demographics of long term NCP 
users: 
Of sustained quitters at 12 months 
women were more likely than men to 
use nicotine gum (p<0.0001) but no 
gender differences for amount used 
(Bjornson=Benson 1993). 
Of sustained quitters at 24 months 
28% of women and 19% of men 
reported current use of nicotine gum 
(Nides 1995). 
Predictors related to long term NCP 
use: 
Among sustained non-smokers 
(n=1069) at 12 months, gum use 
significantly associated with being 
female; lower BMI; smoking history 
(gum use & quit attempts), nicotine 
dependence. Only nicotine 
dependence variables associated 
with using more pieces per day 
(Bjornson=Benson 1993). 
Purchase patterns: 
No information 
Attrition: 
90% (3523/3923) of SI group had 
complete annual 5-year follow-up 
data. 
First author and year:   
Schneider 2003 
Aim of study: 
To evaluate the 
Setting: 
Hospital based smoking 
cessation unit, Switzerland. 
Participants: 
Method of allocation: 
Not applicable. 
Intervention(s): 
Nicotine nasal spray provided 
Primary outcomes: 
Self-reported continuous 
abstinence validated by expired 
CO. Participants admitting 
Length of time of using NCP and/or 
prevalence of use: 
At 18 months 5/12 abstainers still 
using spray. 
Limitations (author):  
Small study size. 
Limitations (review team): 
 Small study size 
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efficacy of prolonged 
administration (18 
months) of a nicotine 
nasal spray in a 
smoking cessation 
program and to 
attempt to characterize 
the pattern of use of 
the nasal spray with a 
specially developed 
electronic monitor in 
an effort to assess the 
factors associated with 
cessation success or 
failure. 
Study Design : 
Prospective cohort 
Quality score: 
+ 
External validity score: 
+ 
 
92 participants referred to SC 
unit Oct 1996 to April 1997 or 
recruited via advert in hospital. 
Male: 49; average age 40 
(range 22-65); education 18 yrs 
range 14-28. 
Inclusion: 
18 yrs plus, smoke at least 15 
cigarettes/day, have smoked 
for more than 5 yrs, highly 
motivated to stop smoking 
Exclusion: 
History of myocardial infarction 
in preceding 3 months, 
pregnancy or breast-feeding, 
use of any form of smokeless 
tobacco or other NRT.  
Motivation of participants: 
Highly motivated to stop 
smoking. 
 
for up to 18 months. Usage 
measured by MDILog device 
attached to spray 
Control: 
Not applicable 
Sample sizes: 
Eligible: 94 
Enrolled 92 
Baseline comparisons: 
Not applicable 
Study power: 
The 95% confidence interval 
obtained was 20% rather 
than the planned 15%. 
Intervention delivery: 
Hospital smoking cessation 
unit 
 
occasional smoking but with a CO 
level less than 10 ppm and willing 
to continue categorised as partial 
successes. 
Secondary outcomes: 
Nicotine nasal spray use 
Follow-up periods: 
Week 2; months 1, 2, 3, 4, 6, 9, 
12, 15, 18, 21 and 24. 
Method of analysis: 
Consumption of the spray 
characterised by median values. 
Fisher’s exact test for discrete 
variables and Mann-Whitney test 
for continuous variables. Findings 
were considered statistically 
significant if p<0.05. 
Demographic, pre-treatment, and 
intra-treatment characteristics 
examined using logistic 
regression models, presented as 
odds ratios with corresponding 
confidence intervals. 
[Participants relapsing during 
study considered failures in the 
analysis. Six participants 
admitting occasional smoking but 
with CO <10ppm and willing to 
continue categorized as partial 
successes.] 
 
At 18 months 3/6 in partial success 
group still using spray. 
At 12 months 8/16 abstainers still 
using spray 
Pattern of NCP use: 
At 18 months 1/5 abstainers was 
using the spray above recommended 
levels (median of 94puffs/day). Of 
the 3 users in the partial success 
group still using the nasal spray, one 
was using 1-15puffs/day, another 
was using 16-30 puffs/day and the 
last more than 30 puffs/day (median 
33 puffs/day).  
Demographics of long term NCP 
users: 
None 
Predictors related to long term NCP 
use: 
All participants using the nasal spray 
at 18 months had high craving scores 
at study start, and all except one still 
mentioned craving as a reason for 
continuing to use the spray. 
Purchase patterns: 
None 
Attrition: 
89% follow-up at 24 months 
 
Evidence gaps: 
None stated. 
Funding sources: 
Pharmacia Upjohn. AARDEX 
Ltd supplied MDILog units 
Applicable to UK? 
Yes 
First author and year:   
Shetty 2010 
Aim of study: 
The effect of a trust-
wide smoke-free policy 
on changes in 
behaviour, incidents 
and prescribing. 
Setting: 
Medium secure hospital, UK 
Participants: 
50 male in-patients 
Inclusion: 
Smokers prior to 
implementation of policy 
Exclusion: 
Method of allocation: 
Not applicable 
Intervention(s): 
Introduction of a smoke free 
policy. Before introduction, 
interventions included 
smoking cessation group and 
individual sessions; NRT 
Primary outcomes: 
Focused on rates of smoking, 
incidents of smoking-related 
verbal and physical aggression, 
use of as and when needed 
tranquillising medication, 
clozapine serum levels and use of 
NRT. 
Length of time of using NCP and/or 
prevalence of use: 
10/50 (20%) participants receiving 
NRT 12 months post-
implementation, of whom four had 
received intermittent NRT for >12 
months. 
Pattern of NCP use: 
Limitations (author):  
None 
Limitations (review team): 
Small sample, retrospective 
analysis, smoking practices 
outside of hospital would 
have been useful. 
Evidence gaps: 
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Study Design : 
Retrospective before 
and after analysis 
Quality score: 
− 
External validity score: 
+ 
 
Non-smokers prior to 
implementation of policy 
Motivation of participants: 
Not provided 
 
provision; staff training; 
engagement with patients 
through posters, individual 
and group discussion and 
patient advocates. 
Control: 
Not applicable 
Sample sizes: 
56 in-patients of whom 50 
were smokers 
How were the data 
collected: 
• What method(s): 
Review of clinical records, 
primary healthcare records 
and incident reports. 
• By whom: 
Authors who are Trust staff. 
• What setting(s): 
Community. 
• When: 
Ban introduced in March 
2007. 
Follow-up periods: 
12 month post-implementation 
Method of analysis: 
Mann-Whitney U test for before 
and after differences. P<0.05 
considered significant. 
None 
Demographics of long term NCP 
users: 
None 
Predictors related to long term NCP 
use: 
None 
Purchase patterns:  
None 
Attrition: 
Not applicable  
 
Evaluation of long term 
impact of smoking ban and 
post-hospital smoking 
behaviour of patients, 
Funding sources: 
No details 
Applicable to UK? 
Yes 
First author and year:   
Shiffman 2003 
Aim of study: 
To estimate the 
incidence of persistent 
use of OTC nicotine 
gum and patch for 
periods of >3 months, ≥ 
6 months, ≥ 12 months 
and ≥ 24 months. 
Study Design : 
Cross-sectional survey 
(Jan 1997-March 2000) 
Quality score: 
Setting: 
Community, USA 
Participants: 
2960 households that 
purchased NRT  
Characteristics of patch and 
gum purchasers, average 
household size =2.6 (P) 2.5 (G); 
median household income 
$42500 (P) $47500 (G);   white 
93.1% (P) 94.6% (G); married 
64.9% (P) 62.0% (G) employed 
79.8% (P) 79.0 (G) any college 
education 73.8% (P) 80.0% (G). 
Sample sizes: 
2960 householders with 2050 
purchasing patch and 805 
purchasing gum, 165 
purchased both. 
How were the data 
collected: 
• What method(s): 
Analysis of purchase data 
provided by AC Nielsen. No 
data collected on use of NRT 
or smoking status were 
collected. 
• By whom: 
Primary outcomes: 
Persistent purchase 
Method of analysis: 
Duration of continuous purchase 
of gum and of patch was 
calculated for each household. 
Because some observations were 
censored (3.9% patch; 5.6% gum) 
continuous use rates were 
estimated in two ways. First, 
incidence of persistent purchase 
evaluated by random selection of 
a single observation per 
household and estimating the 
incidence of persistent use. 
Length of time of using NCP and/or 
prevalence of use: 
No data on actual use. 
Pattern of NCP use: 
No data on actual use. 
Demographics of long term NCP 
users: 
No data on actual use. 
Predictors related to long term NCP 
use: 
No data on actual use. 
Purchase patterns: 
0.05% of households purchased 
patch and 0.4% of household 
Limitations (author):  
No actual use data 
collected. NRT products 
could have been purchased 
and not scanned. 
Household rather than 
individual data. No data on 
smoking status or 
behaviour. No data on 
physician consultations. 
Purchase patterns may shift 
with time as OTC NRT 
becomes more established. 
Limitations (review team): 
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− 
External validity score: 
+ 
 
Inclusion: 
Householders whose scanner 
data included an NRT product 
during the sampling period. 
Exclusion: 
Householders where duration 
of NRT purchase was unknown 
due to entry or exit from panel. 
Motivation of participants: 
No information 
 
Researchers 
• What setting(s): 
Community. 
• When: 
Jan 1997-March 2000. 
Second survival curves were 
constructed, in which the 
denominator of households “at 
risk” was adjusted for censoring. 
The curves show the probability 
of continuous purchase at each 
month, for households under 
observation, with the time point 
of 24 months representing the 
probability of continuous use for 
24 months or more. 
purchased gum for ≥24 months. 0.1% 
of households purchased patch and 
1.0% of household purchased gum 
for ≥12 months.  
Persistent purchase (allowing for a 1 
month gap between purchases): 
0.05% of households purchased 
patch and 1.0% of household 
purchased gum for ≥24 months. 0.4% 
of households purchased patch and 
2.8% of household purchased gum 
for ≥12 months.  
Attrition: 
Not applicable 
As above 
Evidence gaps: 
None. 
Funding sources: 
GlaxoSmithKline Consumer 
Healthcare (GSK) 
Shiffman and Pillitteri 
consultants to GSK for 
smoking cessation. 
Shiffman has an interest in 
a new NRT product.  
Hughes: honoraria, 
consultancy or research 
grants from Bioscience 
Communications, BL 
Seamon, Edelman Public 
Relations, Genatics, Maine 
Medical Center, Pacific 
Pharmaceuticals, Pfizer Inc, 
Pharmacia, Pinney 
Associates, Sanofi 
Pharmaceuticals. 
Burton: GSK employee. 
Applicable to UK? 
Yes 
First author and year:   
Sutherland 1992 
Stapleton 1998 
Aim of study: 
Efficacy and safety of a 
nasal nicotine spray as 
an adjunct to group 
treatment for stopping 
smoking 
Study Design : 
RCT 
Quality score: 
++ 
Setting: 
Maudsley Hospital smokers 
clinic, London, UK 
Participants: 
227 current daily smokers. 
female - C=65.8%, I=62.9%; 
non-manual occupation – 
C=70.3%, I=71.6% 
Inclusion: 
Current daily smokers; 18-68 
years; good health; motivated 
to stop smoking; willing to 
adhere to the trial protocol. 
Method of allocation: 
Drawing of lots. 
Intervention(s): 
Nicotine nasal spray 
1mg/dose with max. 5 doses/ 
hour and 40 doses/day. 
Recommended duration of 
use=3 months. No formal 
dose reduction regimen. 
Control: 
Placebo spray containing 
black pepper oleo resin. 
Sample sizes: 
Primary outcomes: 
Biochemically validated complete 
abstinence 
Secondary outcomes: 
Mood disturbance, cravings for 
cigarettes, withdrawal, side 
effects and positive effects 
Follow-up periods: 
2, 3, 6, 9, and 12 months 
Method of analysis: 
Difference between C & I groups 
assessed by chi square, relapse 
by log rank test. Logistic 
Length of time of using NCP and/or 
prevalence of use: 
None of the abstinent control 
participants used the spray beyond 6 
months, 13/30 abstainers in the 
intervention group were still using 
the spray at 12 months (11% of total 
intervention group). 
Conflicting numbers from Stapleton:
Limitations (author):  
 
Of those remaining abstinent (n=33) 
in the intervention group, 19 used 
the spray for 1 year and 14 for < 1 
year (range 1-39 weeks). There was 
no difference in relapse after 1 year 
None 
Limitations (review team): 
None 
Evidence gaps: 
Investigation of limiting 
duration of spray use on 
therapeutic effect. 
Funding sources: 
MRC and Imperial Cancer 
Research Fund. Kabi 
Pharmacia Therapeutics AB 
supplied nasal sprays. 
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External validity score: 
++ 
 
Exclusion: 
History of cardiovascular 
disease, hypertension, 
diabetes, severe allergy; 
current use of psychotropic 
medication; use of nicotine 
gum in the past year; current 
abuse of alcohol or other drugs; 
pregnancy 
Motivation of participants: 
Motivated to stop smoking 
 
Eligible: 274 
I=116; C=111. Long term 
follow-up - 47 sustained 
abstinence for 1 year (I=33, 
C=14) 
Baseline comparisons: 
No noted differences on 
demographic or smoking 
characteristics. 
Study power: 
Sample size > 200 required to 
detect as significant the 
difference between an 
abstinence rate of 30% for 
the active group and one of 
15% for the placebo group, 
with 80% power and α = 0.05. 
Estimates of abstinence 
based on results of NRT gum 
trial conducted in the same 
clinic. To allow for effect of 
having to assign couples or 
friends to the same spray (to 
preserve blinding), minimum 
sample size set at 220 since 
20% of the sample was 
expected to fall into this 
category. 
Intervention delivery: 
Via hospital smokers clinic 
regression and analysis of 
variance for effect of variables 
and differences between groups. 
in the nicotine group between those 
who used the spray for 1 year and 
those who stopped earlier 
(Difference: 5% (95% CI -33%, 43%). 
Pattern of NCP use: 
None 
Demographics of long term NCP 
users: 
None 
Predictors related to long term NCP 
use: 
None 
Purchase patterns: 
None 
Attrition: 
Follow-up at all points: I = 96%; C =  
95%. 
 
Applicable to UK? 
Yes 
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APPENDIX B: SUMMARY OF QUALITY APPRAISAL – INTERVENTION STUDIES Key to headings (brief summary from Appendix F, NICE 2009):  1.1 Source population described; 1.2 Eligible population 
representative of source ; 1.3 Selected population representative of eligible; 2.1 Population described; 2.2 Intervention/comparison described; 2.3 Allocation concealed; 2.4 Blinded; 2.5 Exposure adequate; 2.6 Contamination low; 2.7 
Other interventions similar in groups; 2.8 All participants accounted for; 2.9 Setting reflects UK practice; 2.10 Intervention reflects UK practice; 3.1 Reliable outcomes; 3.2 Complete outcomes; 3.3 Important outcomes assessed; 3.4 
Relevant outcomes; 3.5 Similar follow up times; 3.6 Meaningful follow up; 4.1 Groups similar at baseline; 4.2 ITT used; 4.3 Sufficient power; 4.4 Estimates of effect size given; 4.5 Appropriate analysis; 4.6 Precision; 5.1 Internally valid; 
5.2 Externally valid; ++ Minimal bias; +Bias unclear; - Risk of bias; nr Not reported; na Not applicable 
Author 
Year 
Study 
design 
Population Method of allocation to intervention (or comparison) Outcomes Analyses Summary 
  1.1 1.2 1.3 2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 2.9 2.10 3.1 3.2 3.3 3.4 3.5 3.6 4.1 4.2 4.3 4.4 4.5 4.6 5.1 5.2 
Blondal 
1999 
RCT + nr nr ++ ++ ++ ++ + ++ ++ ++ + + + ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ + 
Hatsukami 
1993 
UBA − + + nr − nr nr ++ + − ++ + + + − ++ ++ ++ ++ − − nr − + − − + 
LHS 
[Bjornson-
Benson 
1993; 
Murray 
1996; Nides 
1995] 
RCT ++ ++ ++ ++ ++ ++ ++ − ++ ++ ++ ++ + ++ ++ ++ ++ ++ ++ + ++ ++ + ++ + ++ ++ 
Shetty 
2010 
UBA + + + na + na na na na na ++ ++ ++ ++ ++ + ++ na ++ na nr nr nr + nr − + 
Sutherland 
1992 
(and 
Stapleton 
1998) 
RCT + + + ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ + ++ ++ ++ ++ ++ ++ 
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APPENDIX C: SUMMARY OF QUALITY APPRAISAL – CORRELATION STUDIES Key to headings (brief summary from Appendix G, NICE 2009): 1.1 Source population described; 1.2 Eligible population 
representative of source ; 1.3 Selected population representative of eligible; 2.1 selection bias minimised; 2.2 explanatory variables based on sound theoretical basis; 2.3 contamination acceptably low; 2.4 confounding factors 
identified and controlled; 2.5 setting applicable to the UK; 3.1 Reliable outcomes; 3.2 Complete outcomes; 3.3 Important outcomes assessed; 3.4 Relevant outcomes; 3.5 Similar follow up times; 3.6 Meaningful follow up; 4.1 Groups 
similar at baseline; 4.1 study sufficiently powered to detect an effect; multiple explanatory variables considered in the analyses; analytical methods appropriate; precision of association given or calculable; 5.1 Internally valid; 5.2 
Externally valid. ++ Minimal bias; +Bias unclear; - Risk of bias; nr Not reported; na Not applicable 
Author/ Year Study 
design 
Population Method of selection of 
exposure/comparison group 
Outcomes Analyses Summary 
  1.1 1.2 1.3 2.1 2.2 2.3 2.4 2.5 3.1 3.2 3.3 3.4 3.5 4.1 4.2 4.3 4.4 5.1 5.2 
Etter 2009 CSS                  + + 
Etter 2011 CSS                  + − 
Foulds 2011 CSS                  − − 
Hajek 2007 PC ++ ++ ++ ++ nr na + ++ + ++ ++ na ++ nr ++ ++ ++ + ++ 
Heavner 2010 CSS                  − − 
Hughes 2004 CSS                  − ++ 
Johnson 1991 CSS                  − + 
Johnson 1992 CSS                  − + 
Schneider 
2003 
PC + + ++ + nr na ++ + ++ ++ ++ na ++ + ++ ++ ++ + + 
Shiffman 2003 CSS                  − + 
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APPENDIX D:  REVIEW TEAM 
Staff/Resource Description Role 
Ms Fiona Morgan, SURE, 
Cardiff University 
Searching, study selection, quality assessment, data 
extraction and report writing. 
Dr Helen Morgan, SURE, 
Cardiff University 
Project management, searching, study selection, quality 
assessment, data extraction, narrative synthesis and report 
writing  
Dr Alison Weightman, SURE, 
Cardiff University 
Project Director. Quality assessment, data extraction and 
report writing. 
Dr Sarah Whitehead, CISHE, 
Cardiff University 
Study selection, quality assessment, data extraction and 
report writing. 
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